

Union Calendar No. 330

107TH CONGRESS
2^D SESSION

H. R. 4984

[Report No. 107-551, Part 1]

To amend title XVIII of the Social Security Act to provide for a medicare prescription drug benefit.

IN THE HOUSE OF REPRESENTATIVES

JUNE 21, 2002

Mr. TAUZIN introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

JUNE 26, 2002

Reported from the Committee on Energy and Commerce

JUNE 26, 2002

Referral to the Committee on Ways and Means extended for a period ending not later than June 28, 2002

JUNE 28, 2002

Committee on Ways and Means discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed

A BILL

To amend title XVIII of the Social Security Act to provide for a medicare prescription drug benefit.

1 *Be it enacted by the Senate and House of Representa-*
 2 *tives of the United States of America in Congress assembled,*

3 **TITLE I—MEDICARE**
 4 **PRESCRIPTION DRUG BENEFIT**

5 **SEC. 101. ESTABLISHMENT OF A MEDICARE PRESCRIPTION**
 6 **DRUG BENEFIT.**

7 (a) IN GENERAL.—Title XVIII is amended—

8 (1) by redesignating part D as part E; and

9 (2) by inserting after part C the following new
 10 part:

11 “PART D—VOLUNTARY PRESCRIPTION DRUG BENEFIT
 12 PROGRAM

13 “SEC. 1860A. BENEFITS; ELIGIBILITY; ENROLLMENT; AND
 14 COVERAGE PERIOD.

15 “(a) PROVISION OF QUALIFIED PRESCRIPTION DRUG
 16 COVERAGE THROUGH ENROLLMENT IN PLANS.—Subject
 17 to the succeeding provisions of this part, each individual
 18 who is entitled to benefits under part A or is enrolled
 19 under part B is entitled to obtain qualified prescription
 20 drug coverage (described in section 1860B(a)) as follows:

21 “(1) MEDICARE+CHOICE PLAN.—If the indi-
 22 vidual is eligible to enroll in a Medicare+Choice plan
 23 that provides qualified prescription drug coverage
 24 under section 1851(j), the individual may enroll in
 25 the plan and obtain coverage through such plan.

1 “(2) PRESCRIPTION DRUG PLAN.—If the indi-
2 vidual is not enrolled in a Medicare+Choice plan
3 that provides qualified prescription drug coverage,
4 the individual may enroll under this part in a pre-
5 scription drug plan (as defined in section
6 1860J(a)(5)).

7 Such individuals shall have a choice of such plans under
8 section 1860E(d).

9 “(b) GENERAL ELECTION PROCEDURES.—

10 “(1) IN GENERAL.—An individual eligible to
11 make an election under subsection (a) may elect to
12 enroll in a prescription drug plan under this part, or
13 elect the option of qualified prescription drug cov-
14 erage under a Medicare+Choice plan under part C,
15 and to change such election only in such manner
16 and form as may be prescribed by regulations of the
17 Administrator of the Medicare Benefits Administra-
18 tion (appointed under section 1808(b)) (in this part
19 referred to as the ‘Medicare Benefits Administrator’)
20 and only during an election period prescribed in or
21 under this subsection.

22 “(2) ELECTION PERIODS.—

23 “(A) IN GENERAL.—Except as provided in
24 this paragraph, the election periods under this
25 subsection shall be the same as the coverage

1 election periods under the Medicare+Choice
2 program under section 1851(e), including—

3 “(i) annual coordinated election peri-
4 ods; and

5 “(ii) special election periods.

6 In applying the last sentence of section
7 1851(e)(4) (relating to discontinuance of a
8 Medicare+Choice election during the first year
9 of eligibility) under this subparagraph, in the
10 case of an election described in such section in
11 which the individual had elected or is provided
12 qualified prescription drug coverage at the time
13 of such first enrollment, the individual shall be
14 permitted to enroll in a prescription drug plan
15 under this part at the time of the election of
16 coverage under the original fee-for-service plan.

17 “(B) INITIAL ELECTION PERIODS.—

18 “(i) INDIVIDUALS CURRENTLY COV-
19 ERED.—In the case of an individual who is
20 entitled to benefits under part A or en-
21 rolled under part B as of November 1,
22 2004, there shall be an initial election pe-
23 riod of 6 months beginning on that date.

24 “(ii) INDIVIDUAL COVERED IN FU-
25 TURE.—In the case of an individual who is

1 first entitled to benefits under part A or
2 enrolled under part B after such date,
3 there shall be an initial election period
4 which is the same as the initial enrollment
5 period under section 1837(d).

6 “(C) ADDITIONAL SPECIAL ELECTION PE-
7 RIODS.—The Administrator shall establish spe-
8 cial election periods—

9 “(i) in cases of individuals who have
10 and involuntarily lose prescription drug
11 coverage described in subsection (c)(2)(C);

12 “(ii) in cases described in section
13 1837(h) (relating to errors in enrollment),
14 in the same manner as such section applies
15 to part B;

16 “(iii) in the case of an individual who
17 meets such exceptional conditions (includ-
18 ing conditions provided under section
19 1851(e)(4)(D)) as the Administrator may
20 provide; and

21 “(iv) in cases of individuals (as deter-
22 mined by the Administrator) who become
23 eligible for prescription drug assistance
24 under title XIX under section 1935(d).

1 “(c) GUARANTEED ISSUE; COMMUNITY RATING; AND
2 NONDISCRIMINATION.—

3 “(1) GUARANTEED ISSUE.—

4 “(A) IN GENERAL.—An eligible individual
5 who is eligible to elect qualified prescription
6 drug coverage under a prescription drug plan or
7 Medicare+Choice plan at a time during which
8 elections are accepted under this part with re-
9 spect to the plan shall not be denied enrollment
10 based on any health status-related factor (de-
11 scribed in section 2702(a)(1) of the Public
12 Health Service Act) or any other factor.

13 “(B) MEDICARE+CHOICE LIMITATIONS
14 PERMITTED.—The provisions of paragraphs (2)
15 and (3) (other than subparagraph (C)(i), relat-
16 ing to default enrollment) of section 1851(g)
17 (relating to priority and limitation on termi-
18 nation of election) shall apply to PDP sponsors
19 under this subsection.

20 “(2) COMMUNITY-RATED PREMIUM.—

21 “(A) IN GENERAL.—In the case of an indi-
22 vidual who maintains (as determined under sub-
23 paragraph (C)) continuous prescription drug
24 coverage since the date the individual first
25 qualifies to elect prescription drug coverage

1 under this part, a PDP sponsor or
2 Medicare+Choice organization offering a pre-
3 scription drug plan or Medicare+Choice plan
4 that provides qualified prescription drug cov-
5 erage and in which the individual is enrolled
6 may not deny, limit, or condition the coverage
7 or provision of covered prescription drug bene-
8 fits or increase the premium under the plan
9 based on any health status-related factor de-
10 scribed in section 2702(a)(1) of the Public
11 Health Service Act or any other factor.

12 “(B) LATE ENROLLMENT PENALTY.—In
13 the case of an individual who does not maintain
14 such continuous prescription drug coverage (as
15 described in subparagraph (C)), a PDP sponsor
16 or Medicare+Choice organization may (notwith-
17 standing any provision in this title) adjust the
18 premium otherwise applicable or impose a pre-
19 existing condition exclusion with respect to
20 qualified prescription drug coverage in a man-
21 ner that reflects additional actuarial risk in-
22 volved. Such a risk shall be established through
23 an appropriate actuarial opinion of the type de-
24 scribed in subparagraphs (A) through (C) of
25 section 2103(c)(4).

“(C) CONTINUOUS PRESCRIPTION DRUG
COVERAGE.—An individual is considered for
purposes of this part to be maintaining continuous
prescription drug coverage on and after
the date the individual first qualifies to elect
prescription drug coverage under this part if
the individual establishes that as of such date
the individual is covered under any of the following
prescription drug coverage and before
the date that is the last day of the 63-day period
that begins on the date of termination of
the particular prescription drug coverage involved
(regardless of whether the individual subsequently
obtains any of the following prescription drug coverage):

“(i) COVERAGE UNDER PRESCRIPTION
DRUG PLAN OR MEDICARE+CHOICE
PLAN.—Qualified prescription drug coverage
under a prescription drug plan or
under a Medicare+Choice plan.

“(ii) MEDICAID PRESCRIPTION DRUG
COVERAGE.—Prescription drug coverage
under a medicaid plan under title XIX, including
through the Program of All-inclusive Care for the
Elderly (PACE) under

1 section 1934, through a social health main-
2 tenance organization (referred to in section
3 4104(c) of the Balanced Budget Act of
4 1997), or through a Medicare+Choice
5 project that demonstrates the application
6 of capitation payment rates for frail elderly
7 medicare beneficiaries through the use of a
8 interdisciplinary team and through the
9 provision of primary care services to such
10 beneficiaries by means of such a team at
11 the nursing facility involved.

12 “(iii) PRESCRIPTION DRUG COVERAGE
13 UNDER GROUP HEALTH PLAN.—Any out-
14 patient prescription drug coverage under a
15 group health plan, including a health bene-
16 fits plan under the Federal Employees
17 Health Benefit Plan under chapter 89 of
18 title 5, United States Code, and a qualified
19 retiree prescription drug plan as defined in
20 section 1860H(f)(1), but only if (subject to
21 subparagraph (E)(ii)) the coverage pro-
22 vides benefits at least equivalent to the
23 benefits under a qualified prescription drug
24 plan.

1 “(iv) PRESCRIPTION DRUG COVERAGE
2 UNDER CERTAIN MEDIGAP POLICIES.—
3 Coverage under a medicare supplemental
4 policy under section 1882 that provides
5 benefits for prescription drugs (whether or
6 not such coverage conforms to the stand-
7 ards for packages of benefits under section
8 1882(p)(1)), but only if the policy was in
9 effect on January 1, 2005, and if (subject
10 to subparagraph (E)(ii)) the coverage pro-
11 vides benefits at least equivalent to the
12 benefits under a qualified prescription drug
13 plan.

14 “(v) STATE PHARMACEUTICAL ASSIST-
15 ANCE PROGRAM.—Coverage of prescription
16 drugs under a State pharmaceutical assist-
17 ance program, but only if (subject to sub-
18 paragraph (E)(ii)) the coverage provides
19 benefits at least equivalent to the benefits
20 under a qualified prescription drug plan.

21 “(vi) VETERANS’ COVERAGE OF PRE-
22 SCRIPTION DRUGS.—Coverage of prescrip-
23 tion drugs for veterans under chapter 17
24 of title 38, United States Code, but only if
25 (subject to subparagraph (E)(ii)) the cov-

1 erage provides benefits at least equivalent
2 to the benefits under a qualified prescrip-
3 tion drug plan.

4 “(D) CERTIFICATION.—For purposes of
5 carrying out this paragraph, the certifications
6 of the type described in sections 2701(e) of the
7 Public Health Service Act and in section
8 9801(e) of the Internal Revenue Code shall also
9 include a statement for the period of coverage
10 of whether the individual involved had prescrip-
11 tion drug coverage described in subparagraph
12 (C).

13 “(E) DISCLOSURE.—

14 “(i) IN GENERAL.—Each entity that
15 offers coverage of the type described in
16 clause (iii), (iv), (v), or (vi) of subpara-
17 graph (C) shall provide for disclosure, con-
18 sistent with standards established by the
19 Administrator, of whether such coverage
20 provides benefits at least equivalent to the
21 benefits under a qualified prescription drug
22 plan.

23 “(ii) WAIVER OF LIMITATIONS.—An
24 individual may apply to the Administrator
25 to waive the requirement that coverage of

1 such type provide benefits at least equiva-
2 lent to the benefits under a qualified pre-
3 scription drug plan, if the individual estab-
4 lishes that the individual was not ade-
5 quately informed that such coverage did
6 not provide such level of benefits.

7 “(F) CONSTRUCTION.—Nothing in this
8 section shall be construed as preventing the
9 disenrollment of an individual from a prescrip-
10 tion drug plan or a Medicare+Choice plan
11 based on the termination of an election de-
12 scribed in section 1851(g)(3), including for non-
13 payment of premiums or for other reasons spec-
14 ified in subsection (d)(3), which takes into ac-
15 count a grace period described in section
16 1851(g)(3)(B)(i).

17 “(3) NONDISCRIMINATION.—A PDP sponsor of-
18 fering a prescription drug plan shall not establish a
19 service area in a manner that would discriminate
20 based on health or economic status of potential en-
21 rollees.

22 “(d) EFFECTIVE DATE OF ELECTIONS.—

23 “(1) IN GENERAL.—Except as provided in this
24 section, the Administrator shall provide that elec-
25 tions under subsection (b) take effect at the same

1 time as the Administrator provides that similar elec-
2 tions under section 1851(e) take effect under section
3 1851(f).

4 “(2) NO ELECTION EFFECTIVE BEFORE 2005.—
5 In no case shall any election take effect before Janu-
6 ary 1, 2005.

7 “(3) TERMINATION.—The Administrator shall
8 provide for the termination of an election in the case
9 of—

10 “(A) termination of coverage under both
11 part A and part B; and

12 “(B) termination of elections described in
13 section 1851(g)(3) (including failure to pay re-
14 quired premiums).

15 **“SEC. 1860B. REQUIREMENTS FOR QUALIFIED PRESCRIP-**
16 **TION DRUG COVERAGE.**

17 “(a) REQUIREMENTS.—

18 “(1) IN GENERAL.—For purposes of this part
19 and part C, the term ‘qualified prescription drug
20 coverage’ means either of the following:

21 “(A) STANDARD COVERAGE WITH ACCESS
22 TO NEGOTIATED PRICES.—Standard coverage
23 (as defined in subsection (b)) and access to ne-
24 gotiated prices under subsection (d).

1 “(B) ACTUARIALLY EQUIVALENT COV-
2 ERAGE WITH ACCESS TO NEGOTIATED
3 PRICES.—Coverage of covered outpatient drugs
4 which meets the alternative coverage require-
5 ments of subsection (c) and access to negotiated
6 prices under subsection (d), but only if it is ap-
7 proved by the Administrator, as provided under
8 subsection (c).

9 “(2) PERMITTING ADDITIONAL OUTPATIENT
10 PRESCRIPTION DRUG COVERAGE.—

11 “(A) IN GENERAL.—Subject to subpara-
12 graph (B), nothing in this part shall be con-
13 strued as preventing qualified prescription drug
14 coverage from including coverage of covered
15 outpatient drugs that exceeds the coverage re-
16 quired under paragraph (1), but any such addi-
17 tional coverage shall be limited to coverage of
18 covered outpatient drugs.

19 “(B) DISAPPROVAL AUTHORITY.—The Ad-
20 ministrator shall review the offering of qualified
21 prescription drug coverage under this part or
22 part C. If the Administrator finds that, in the
23 case of a qualified prescription drug coverage
24 under a prescription drug plan or a
25 Medicare+Choice plan, that the organization or

1 sponsor offering the coverage is engaged in ac-
2 tivities intended to discourage enrollment of
3 classes of eligible medicare beneficiaries obtain-
4 ing coverage through the plan on the basis of
5 their higher likelihood of utilizing prescription
6 drug coverage, the Administrator may termi-
7 nate the contract with the sponsor or organiza-
8 tion under this part or part C.

9 “(3) APPLICATION OF SECONDARY PAYOR PRO-
10 VISIONS.—The provisions of section 1852(a)(4) shall
11 apply under this part in the same manner as they
12 apply under part C.

13 “(b) STANDARD COVERAGE.—For purposes of this
14 part, the ‘standard coverage’ is coverage of covered out-
15 patient drugs (as defined in subsection (f)) that meets the
16 following requirements:

17 “(1) DEDUCTIBLE.—The coverage has an an-
18 nual deductible—

19 “(A) for 2005, that is equal to \$250; or

20 “(B) for a subsequent year, that is equal
21 to the amount specified under this paragraph
22 for the previous year increased by the percent-
23 age specified in paragraph (5) for the year in-
24 volved.

1 Any amount determined under subparagraph (B)
2 that is not a multiple of \$10 shall be rounded to the
3 nearest multiple of \$10.

4 “(2) LIMITS ON COST-SHARING.—

5 “(A) IN GENERAL.—The coverage has
6 cost-sharing (for costs above the annual deduct-
7 ible specified in paragraph (1) and up to the
8 initial coverage limit under paragraph (3)) as
9 follows:

10 “(i) FIRST COPAYMENT RANGE.—For
11 costs above the annual deductible specified
12 in paragraph (1) and up to amount speci-
13 fied in subparagraph (C), the cost-
14 sharing—

15 “(I) is equal to 20 percent; or

16 “(II) is actuarially equivalent
17 (using processes established under
18 subsection (e)) to an average expected
19 payment of 20 percent of such costs.

20 “(ii) SECONDARY COPAYMENT
21 RANGE.—For costs above the amount spec-
22 ified in subparagraph (C) and up to the
23 initial coverage limit, the cost-sharing—

24 “(I) is equal to 50 percent; or

1 “(II) is actuarially consistent
2 (using processes established under
3 subsection (e)) with an average ex-
4 pected payment of 50 percent of such
5 costs.

6 “(B) USE OF TIERED COPAYMENTS.—
7 Nothing in this part shall be construed as pre-
8 venting a PDP sponsor from applying tiered co-
9 payments, so long as such tiered copayments
10 are consistent with subparagraph (A).

11 “(C) INITIAL COPAYMENT THRESHOLD.—
12 The amount specified in this subparagraph—
13 “(i) for 2005, is equal to \$1,000; or
14 “(ii) for a subsequent year, is equal to
15 the amount specified in this subparagraph
16 for the previous year, increased by the an-
17 nual percentage increase described in para-
18 graph (5) for the year involved.

19 Any amount determined under clause (ii) that
20 is not a multiple of \$10 shall be rounded to the
21 nearest multiple of \$10.

22 “(3) INITIAL COVERAGE LIMIT.—Subject to
23 paragraph (4), the coverage has an initial coverage
24 limit on the maximum costs that may be recognized

1 for payment purposes (above the annual deduct-
2 ible)—

3 “(A) for 2005, that is equal to \$2,000; or

4 “(B) for a subsequent year, that is equal
5 to the amount specified in this paragraph for
6 the previous year, increased by the annual per-
7 centage increase described in paragraph (5) for
8 the year involved.

9 Any amount determined under subparagraph (B)
10 that is not a multiple of \$25 shall be rounded to the
11 nearest multiple of \$25.

12 “(4) CATASTROPHIC PROTECTION.—

13 “(A) IN GENERAL.—Notwithstanding para-
14 graph (3), the coverage provides benefits with
15 no cost-sharing after the individual has in-
16 curred costs (as described in subparagraph (C))
17 for covered outpatient drugs in a year equal to
18 the annual out-of-pocket threshold specified in
19 subparagraph (B).

20 “(B) ANNUAL OUT-OF-POCKET THRESH-
21 OLD.—For purposes of this part, the ‘annual
22 out-of-pocket threshold’ specified in this
23 subparagraph—

24 “(i) for 2005, is equal to \$3,700; or

1 “(ii) for a subsequent year, is equal to
2 the amount specified in this subparagraph
3 for the previous year, increased by the an-
4 nual percentage increase described in para-
5 graph (5) for the year involved.

6 Any amount determined under clause (ii) that
7 is not a multiple of \$100 shall be rounded to
8 the nearest multiple of \$100.

9 “(C) APPLICATION.—In applying subpara-
10 graph (A)—

11 “(i) incurred costs shall only include
12 costs incurred for the annual deductible
13 (described in paragraph (1)), cost-sharing
14 (described in paragraph (2)), and amounts
15 for which benefits are not provided because
16 of the application of the initial coverage
17 limit described in paragraph (3); and

18 “(ii) such costs shall be treated as in-
19 curred only if they are paid by the indi-
20 vidual (or by another individual, such as a
21 family member, on behalf of the indi-
22 vidual), under section 1860G, or under
23 title XIX and the individual (or other indi-
24 vidual) is not reimbursed through insur-
25 ance or otherwise, a group health plan, or

1 other third-party payment arrangement for
2 such costs.

3 “(5) ANNUAL PERCENTAGE INCREASE.—For
4 purposes of this part, the annual percentage increase
5 specified in this paragraph for a year is equal to the
6 annual percentage increase in average per capita ag-
7 gregate expenditures for covered outpatient drugs in
8 the United States for medicare beneficiaries, as de-
9 termined by the Administrator for the 12-month pe-
10 riod ending in July of the previous year.

11 “(c) ALTERNATIVE COVERAGE REQUIREMENTS.—A
12 prescription drug plan or Medicare+Choice plan may pro-
13 vide a different prescription drug benefit design from the
14 standard coverage described in subsection (b) so long as
15 the Administrator determines (based on an actuarial anal-
16 ysis by the Administrator) the following requirements are
17 met and the plan applies for, and receives, the approval
18 of the Administrator for such benefit design:

19 “(1) ASSURING AT LEAST ACTUARIALLY EQUIV-
20 ALENT COVERAGE.—

21 “(A) ASSURING EQUIVALENT VALUE OF
22 TOTAL COVERAGE.—The actuarial value of the
23 total coverage (as determined under subsection
24 (e)) is at least equal to the actuarial value (as
25 so determined) of standard coverage.

1 “(B) ASSURING EQUIVALENT UNSUB-
2 SIDIZED VALUE OF COVERAGE.—The unsub-
3 sidized value of the coverage is at least equal to
4 the unsubsidized value of standard coverage.
5 For purposes of this subparagraph, the unsub-
6 sidized value of coverage is the amount by
7 which the actuarial value of the coverage (as
8 determined under subsection (e)) exceeds the
9 actuarial value of the subsidy payments under
10 section 1860H with respect to such coverage.

11 “(C) ASSURING STANDARD PAYMENT FOR
12 COSTS AT INITIAL COVERAGE LIMIT.—The cov-
13 erage is designed, based upon an actuarially
14 representative pattern of utilization (as deter-
15 mined under subsection (e)), to provide for the
16 payment, with respect to costs incurred that are
17 equal to the initial coverage limit under sub-
18 section (b)(3), of an amount equal to at least
19 the sum of the following products:

20 “(i) FIRST COPAYMENT RANGE.—The
21 product of—

22 “(I) the amount by which the ini-
23 tial copayment threshold described in
24 subsection (b)(2)(C) exceeds the de-

1 ductible described in subsection
2 (b)(1); and

3 “(II) 100 percent minus the cost-
4 sharing percentage specified in sub-
5 section (b)(2)(A)(i)(I).

6 “(ii) SECONDARY COPAYMENT
7 RANGE.—The product of—

8 “(I) the amount by which the ini-
9 tial coverage limit described in sub-
10 section (b)(3) exceeds the initial co-
11 payment threshold described in sub-
12 section (b)(2)(C); and

13 “(II) 100 percent minus the cost-
14 sharing percentage specified in sub-
15 section (b)(2)(A)(ii)(I).

16 “(2) CATASTROPHIC PROTECTION.—The cov-
17 erage provides for beneficiaries the catastrophic pro-
18 tection described in subsection (b)(4).

19 “(d) ACCESS TO NEGOTIATED PRICES.—

20 “(1) IN GENERAL.—Under qualified prescrip-
21 tion drug coverage offered by a PDP sponsor or a
22 Medicare+Choice organization, the sponsor or orga-
23 nization shall provide beneficiaries with access to ne-
24 gotiated prices (including applicable discounts) used
25 for payment for covered outpatient drugs, regardless

1 of the fact that no benefits may be payable under
2 the coverage with respect to such drugs because of
3 the application of cost-sharing or an initial coverage
4 limit (described in subsection (b)(3)). Insofar as a
5 State elects to provide medical assistance under title
6 XIX for a drug based on the prices negotiated by a
7 prescription drug plan under this part, the require-
8 ments of section 1927 shall not apply to such drugs.
9 The prices negotiated by a prescription drug plan
10 under this part, by a Medicare+Choice plan with re-
11 spect to covered outpatient drugs, or by a qualified
12 retiree prescription drug plan (as defined in section
13 1860H(f)(1)) with respect to such drugs on behalf
14 of individuals entitled to benefits under part A or
15 enrolled under part B, shall (notwithstanding any
16 other provision of law) not be taken into account for
17 the purposes of establishing the best price under sec-
18 tion 1927(c)(1)(C).

19 “(2) DISCLOSURE.—The PDP sponsor or
20 Medicare+Choice organization shall disclose to the
21 Administrator (in a manner specified by the Admin-
22 istrator) the extent to which discounts or rebates
23 made available to the sponsor or organization by a
24 manufacturer are passed through to enrollees
25 through pharmacies and other dispensers or other-

1 wise. The provisions of section 1927(b)(3)(D) shall
2 apply to information disclosed to the Administrator
3 under this paragraph in the same manner as such
4 provisions apply to information disclosed under such
5 section.

6 “(e) ACTUARIAL VALUATION; DETERMINATION OF
7 ANNUAL PERCENTAGE INCREASES.—

8 “(1) PROCESSES.—For purposes of this section,
9 the Administrator shall establish processes and
10 methods—

11 “(A) for determining the actuarial valu-
12 ation of prescription drug coverage, including—

13 “(i) an actuarial valuation of standard
14 coverage and of the reinsurance subsidy
15 payments under section 1860H;

16 “(ii) the use of generally accepted ac-
17 tuarial principles and methodologies; and

18 “(iii) applying the same methodology
19 for determinations of alternative coverage
20 under subsection (c) as is used with re-
21 spect to determinations of standard cov-
22 erage under subsection (b); and

23 “(B) for determining annual percentage in-
24 creases described in subsection (b)(5).

1 “(2) USE OF OUTSIDE ACTUARIES.—Under the
2 processes under paragraph (1)(A), PDP sponsors
3 and Medicare+Choice organizations may use actu-
4 arial opinions certified by independent, qualified ac-
5 tuaries to establish actuarial values, but the Admin-
6 istrator shall determine whether such actuarial val-
7 ues meet the requirements under subsection (c)(1).

8 “(f) COVERED OUTPATIENT DRUGS DEFINED.—

9 “(1) IN GENERAL.—Except as provided in this
10 subsection, for purposes of this part, the term ‘cov-
11 ered outpatient drug’ means—

12 “(A) a drug that may be dispensed only
13 upon a prescription and that is described in
14 subparagraph (A)(i) or (A)(ii) of section
15 1927(k)(2); or

16 “(B) a biological product described in
17 clauses (i) through (iii) of subparagraph (B) of
18 such section or insulin described in subpara-
19 graph (C) of such section,

20 and such term includes a vaccine licensed under sec-
21 tion 351 of the Public Health Service Act and any
22 use of a covered outpatient drug for a medically ac-
23 cepted indication (as defined in section 1927(k)(6)).

24 “(2) EXCLUSIONS.—

1 “(A) IN GENERAL.—Such term does not
2 include drugs or classes of drugs, or their med-
3 ical uses, which may be excluded from coverage
4 or otherwise restricted under section
5 1927(d)(2), other than subparagraph (E) there-
6 of (relating to smoking cessation agents), or
7 under section 1927(d)(3).

8 “(B) AVOIDANCE OF DUPLICATE COV-
9 ERAGE.—A drug prescribed for an individual
10 that would otherwise be a covered outpatient
11 drug under this part shall not be so considered
12 if payment for such drug is available under part
13 A or B for an individual entitled to benefits
14 under part A and enrolled under part B.

15 “(3) APPLICATION OF FORMULARY RESTRIC-
16 TIONS.—A drug prescribed for an individual that
17 would otherwise be a covered outpatient drug under
18 this part shall not be so considered under a plan if
19 the plan excludes the drug under a formulary and
20 such exclusion is not successfully appealed under
21 section 1860C(f)(2).

22 “(4) APPLICATION OF GENERAL EXCLUSION
23 PROVISIONS.—A prescription drug plan or
24 Medicare+Choice plan may exclude from qualified

1 prescription drug coverage any covered outpatient
2 drug—

3 “(A) for which payment would not be
4 made if section 1862(a) applied to part D; or
5 “(B) which are not prescribed in accord-
6 ance with the plan or this part.

7 Such exclusions are determinations subject to recon-
8 sideration and appeal pursuant to section 1860C(f).

9 **“SEC. 1860C. BENEFICIARY PROTECTIONS FOR QUALIFIED**
10 **PRESCRIPTION DRUG COVERAGE.**

11 “(a) GUARANTEED ISSUE, COMMUNITY-RELATED
12 PREMIUMS, ACCESS TO NEGOTIATED PRICES, AND NON-
13 DISCRIMINATION.—For provisions requiring guaranteed
14 issue, community-rated premiums, access to negotiated
15 prices, and nondiscrimination, see sections 1860A(c)(1),
16 1860A(c)(2), 1860B(d), and 1860F(b), respectively.

17 “(b) DISSEMINATION OF INFORMATION.—

18 “(1) GENERAL INFORMATION.—A PDP sponsor
19 shall disclose, in a clear, accurate, and standardized
20 form to each enrollee with a prescription drug plan
21 offered by the sponsor under this part at the time
22 of enrollment and at least annually thereafter, the
23 information described in section 1852(c)(1) relating
24 to such plan. Such information includes the fol-
25 lowing:

1 “(A) Access to covered outpatient drugs,
2 including access through pharmacy networks.

3 “(B) How any formulary used by the spon-
4 sor functions.

5 “(C) Co-payments and deductible require-
6 ments, including the identification of the tiered
7 or other co-payment level applicable to each
8 drug (or class of drugs).

9 “(D) Grievance and appeals procedures.

10 “(2) DISCLOSURE UPON REQUEST OF GENERAL
11 COVERAGE, UTILIZATION, AND GRIEVANCE INFORMA-
12 TION.—Upon request of an individual eligible to en-
13 roll under a prescription drug plan, the PDP spon-
14 sor shall provide the information described in section
15 1852(c)(2) (other than subparagraph (D)) to such
16 individual.

17 “(3) RESPONSE TO BENEFICIARY QUESTIONS.—
18 Each PDP sponsor offering a prescription drug plan
19 shall have a mechanism for providing specific infor-
20 mation to enrollees upon request. The sponsor shall
21 make available on a timely basis, through an Inter-
22 net website and in writing upon request, information
23 on specific changes in its formulary.

24 “(4) CLAIMS INFORMATION.—Each PDP spon-
25 sor offering a prescription drug plan must furnish to

1 enrolled individuals in a form easily understandable
2 to such individuals an explanation of benefits (in ac-
3 cordance with section 1806(a) or in a comparable
4 manner) and a notice of the benefits in relation to
5 initial coverage limit and annual out-of-pocket
6 threshold for the current year, whenever prescription
7 drug benefits are provided under this part (except
8 that such notice need not be provided more often
9 than monthly).

10 “(c) ACCESS TO COVERED BENEFITS.—

11 “(1) ASSURING PHARMACY ACCESS.—

12 “(A) IN GENERAL.—The PDP sponsor of
13 the prescription drug plan shall secure the par-
14 ticipation in its network of a sufficient number
15 of pharmacies that dispense (other than by mail
16 order) drugs directly to patients to ensure con-
17 venient access (as determined by the Adminis-
18 trator and including adequate emergency ac-
19 cess) for enrolled beneficiaries, in accordance
20 with standards established under section
21 1860D(e) that ensure such convenient access.

22 “(B) USE OF POINT-OF-SERVICE SYS-
23 TEM.—A PDP sponsor shall establish an op-
24 tional point-of-service method of operation
25 under which—

1 “(i) the plan provides access to any or
2 all pharmacies that are not participating
3 pharmacies in its network; and

4 “(ii) the plan may charge beneficiaries
5 through adjustments in premiums and co-
6 payments any additional costs associated
7 with the point-of-service option.

8 The additional copayments so charged shall not
9 count toward the application of section
10 1860B(b).

11 “(2) USE OF STANDARDIZED TECHNOLOGY.—

12 “(A) IN GENERAL.—The PDP sponsor of
13 a prescription drug plan shall issue (and re-
14 issue, as appropriate) such a card (or other
15 technology) that may be used by an enrolled
16 beneficiary to assure access to negotiated prices
17 under section 1860B(d) for the purchase of
18 prescription drugs for which coverage is not
19 otherwise provided under the prescription drug
20 plan.

21 “(B) STANDARDS.—

22 “(i) DEVELOPMENT.—The Adminis-
23 trator shall provide for the development of
24 national standards relating to a standard-
25 ized format for the card or other tech-

1 nology referred to in subparagraph (A).
2 Such standards shall be compatible with
3 standards established under part C of title
4 XI.

5 “(ii) APPLICATION OF ADVISORY TASK
6 FORCE.—The advisory task force estab-
7 lished under subsection (d)(3)(B)(ii) shall
8 provide recommendations to the Adminis-
9 trator under such subsection regarding the
10 standards developed under clause (i).

11 “(3) REQUIREMENTS ON DEVELOPMENT AND
12 APPLICATION OF FORMULARIES.—If a PDP sponsor
13 of a prescription drug plan uses a formulary, the fol-
14 lowing requirements must be met:

15 “(A) PHARMACY AND THERAPEUTIC (P&T)
16 COMMITTEE.—The sponsor must establish a
17 pharmacy and therapeutic committee that de-
18 velops and reviews the formulary. Such com-
19 mittee shall include at least one physician and
20 at least one pharmacist both with expertise in
21 the care of elderly or disabled persons and a
22 majority of its members shall consist of individ-
23 uals who are a physician or a pharmacist (or
24 both).

1 “(B) FORMULARY DEVELOPMENT.—In de-
2 veloping and reviewing the formulary, the com-
3 mittee shall base clinical decisions on the
4 strength of scientific evidence and standards of
5 practice, including assessing peer-reviewed med-
6 ical literature, such as randomized clinical
7 trials, pharmacoeconomic studies, outcomes re-
8 search data, and such other information as the
9 committee determines to be appropriate.

10 “(C) INCLUSION OF DRUGS IN ALL THERA-
11 PEUTIC CATEGORIES.—The formulary must in-
12 clude drugs within each therapeutic category
13 and class of covered outpatient drugs (although
14 not necessarily for all drugs within such cat-
15 egories and classes).

16 “(D) PROVIDER EDUCATION.—The com-
17 mittee shall establish policies and procedures to
18 educate and inform health care providers con-
19 cerning the formulary.

20 “(E) NOTICE BEFORE REMOVING DRUGS
21 FROM FORMULARY.—Any removal of a drug
22 from a formulary shall take effect only after ap-
23 propriate notice is made available to bene-
24 ficiaries and physicians.

1 “(F) GRIEVANCES AND APPEALS RELAT-
2 ING TO APPLICATION OF FORMULARIES.—For
3 provisions relating to grievances and appeals of
4 coverage, see subsections (e) and (f).

5 “(d) COST AND UTILIZATION MANAGEMENT; QUAL-
6 ITY ASSURANCE; MEDICATION THERAPY MANAGEMENT
7 PROGRAM.—

8 “(1) IN GENERAL.—The PDP sponsor shall
9 have in place with respect to covered outpatient
10 drugs—

11 “(A) an effective cost and drug utilization
12 management program, including medically ap-
13 propriate incentives to use generic drugs and
14 therapeutic interchange, when appropriate;

15 “(B) quality assurance measures and sys-
16 tems to reduce medical errors and adverse drug
17 interactions, including a medication therapy
18 management program described in paragraph
19 (2) and for years beginning with 2006, an elec-
20 tronic prescription program described in para-
21 graph (3); and

22 “(C) a program to control fraud, abuse,
23 and waste.

24 Nothing in this section shall be construed as impair-
25 ing a PDP sponsor from applying cost management

1 tools (including differential payments) under all
2 methods of operation.

3 “(2) MEDICATION THERAPY MANAGEMENT PRO-
4 GRAM.—

5 “(A) IN GENERAL.—A medication therapy
6 management program described in this para-
7 graph is a program of drug therapy manage-
8 ment and medication administration that is de-
9 signed to assure, with respect to beneficiaries
10 with chronic diseases (such as diabetes, asthma,
11 hypertension, and congestive heart failure) or
12 multiple prescriptions, that covered outpatient
13 drugs under the prescription drug plan are ap-
14 propriately used to achieve therapeutic goals
15 and reduce the risk of adverse events, including
16 adverse drug interactions.

17 “(B) ELEMENTS.—Such program may
18 include—

19 “(i) enhanced beneficiary under-
20 standing of such appropriate use through
21 beneficiary education, counseling, and
22 other appropriate means;

23 “(ii) increased beneficiary adherence
24 with prescription medication regimens
25 through medication refill reminders, special

1 packaging, and other appropriate means;
2 and

3 “(iii) detection of patterns of overuse
4 and underuse of prescription drugs.

5 “(C) DEVELOPMENT OF PROGRAM IN CO-
6 OPERATION WITH LICENSED PHARMACISTS.—
7 The program shall be developed in cooperation
8 with licensed pharmacists and physicians.

9 “(D) CONSIDERATIONS IN PHARMACY
10 FEES.—The PDP sponsor of a prescription
11 drug program shall take into account, in estab-
12 lishing fees for pharmacists and others pro-
13 viding services under the medication therapy
14 management program, the resources and time
15 used in implementing the program.

16 “(3) ELECTRONIC PRESCRIPTION PROGRAM.—

17 “(A) IN GENERAL.—An electronic prescrip-
18 tion drug program described in this paragraph
19 is a program that includes at least the following
20 components, consistent with national standards
21 established under subparagraph (B):

22 “(i) ELECTRONIC TRANSMITTAL OF
23 PRESCRIPTIONS.—Prescriptions are only
24 received electronically, except in emergency

1 cases and other exceptional circumstances
2 recognized by the Administrator.

3 “(ii) PROVISION OF INFORMATION TO
4 PRESCRIBING HEALTH CARE PROFES-
5 SIONAL.—The program provides, upon
6 transmittal of a prescription by a pre-
7 scribing health care professional, for trans-
8 mittal by the pharmacist to the profes-
9 sional of information that includes—

10 “(I) information (to the extent
11 available and feasible) on the drugs
12 being prescribed for that patient and
13 other information relating to the med-
14 ical history or condition of the patient
15 that may be relevant to the appro-
16 priate prescription for that patient;

17 “(II) cost-effective alternatives (if
18 any) for the use of the drug pre-
19 scribed; and

20 “(III) information on the drugs
21 included in the applicable formulary.

22 To the extent feasible, such program shall
23 permit the prescribing health care profes-
24 sional to provide (and be provided) related

1 information on an interactive, real-time
2 basis.

3 “(B) STANDARDS.—

4 “(i) DEVELOPMENT.—The Adminis-
5 trator shall provide for the development of
6 national standards relating to the elec-
7 tronic prescription drug program described
8 in subparagraph (A). Such standards shall
9 be compatible with standards established
10 under part C of title XI.

11 “(ii) ADVISORY TASK FORCE.—In de-
12 veloping such standards and the standards
13 described in subsection (c)(2)(B)(i) the Ad-
14 ministrator shall establish a task force that
15 includes representatives of physicians, hos-
16 pitals, pharmacists, and technology experts
17 and representatives of the Departments of
18 Veterans Affairs and Defense and other
19 appropriate Federal agencies to provide
20 recommendations to the Administrator on
21 such standards, including recommenda-
22 tions relating to the following:

23 “(I) The range of available com-
24 puterized prescribing software and

1 hardware and their costs to develop
2 and implement.

3 “(II) The extent to which such
4 systems reduce medication errors and
5 can be readily implemented by physi-
6 cians and hospitals.

7 “(III) Efforts to develop a com-
8 mon software platform for computer-
9 ized prescribing.

10 “(IV) The cost of implementing
11 such systems in the range of hospital
12 and physician office settings, includ-
13 ing hardware, software, and training
14 costs.

15 “(V) Implementation issues as
16 they relate to part C of title XI, and
17 current Federal and State prescribing
18 laws and regulations and their impact
19 on implementation of computerized
20 prescribing.

21 “(iii) DEADLINES.—

22 “(I) The Administrator shall con-
23 stitute the task force under clause (ii)
24 by not later than April 1, 2003.

1 “(II) Such task force shall sub-
2 mit recommendations to Adminis-
3 trator by not later than January 1,
4 2004.

5 “(III) The Administrator shall
6 develop and promulgate the national
7 standards referred to in clause (ii) by
8 not later than July 1, 2004.

9 “(C) REFERENCE TO AVAILABILITY OF
10 GRANT FUNDS.—Grant funds are authorized
11 under section 3990 of the Public Health Serv-
12 ice Act to provide assistance to health care pro-
13 viders in implementing electronic prescription
14 drug programs.

15 “(4) TREATMENT OF ACCREDITATION.—Section
16 1852(e)(4) (relating to treatment of accreditation)
17 shall apply to prescription drug plans under this
18 part with respect to the following requirements, in
19 the same manner as they apply to Medicare+Choice
20 plans under part C with respect to the requirements
21 described in a clause of section 1852(e)(4)(B):

22 “(A) Paragraph (1) (including quality as-
23 surance), including medication therapy manage-
24 ment program under paragraph (2).

1 “(B) Subsection (c)(1) (relating to access
2 to covered benefits).

3 “(C) Subsection (g) (relating to confiden-
4 tiality and accuracy of enrollee records).

5 “(5) PUBLIC DISCLOSURE OF PHARMACEUTICAL
6 PRICES FOR EQUIVALENT DRUGS.—Each PDP spon-
7 sor shall provide that each pharmacy or other dis-
8 penser that arranges for the dispensing of a covered
9 outpatient drug shall inform the beneficiary at the
10 time of purchase of the drug of any differential be-
11 tween the price of the prescribed drug to the enrollee
12 and the price of the lowest cost generic drug covered
13 under the plan that is therapeutically equivalent and
14 bioequivalent.

15 “(e) GRIEVANCE MECHANISM, COVERAGE DETER-
16 MINATIONS, AND RECONSIDERATIONS.—

17 “(1) IN GENERAL.—Each PDP sponsor shall
18 provide meaningful procedures for hearing and re-
19 solving grievances between the organization (includ-
20 ing any entity or individual through which the spon-
21 sor provides covered benefits) and enrollees with pre-
22 scription drug plans of the sponsor under this part
23 in accordance with section 1852(f).

24 “(2) APPLICATION OF COVERAGE DETERMINA-
25 TION AND RECONSIDERATION PROVISIONS.—A PDP

1 sponsor shall meet the requirements of paragraphs
2 (1) through (3) of section 1852(g) with respect to
3 covered benefits under the prescription drug plan it
4 offers under this part in the same manner as such
5 requirements apply to a Medicare+Choice organiza-
6 tion with respect to benefits it offers under a
7 Medicare+Choice plan under part C.

8 “(3) REQUEST FOR REVIEW OF TIERED FOR-
9 MULARY DETERMINATIONS.—In the case of a pre-
10 scription drug plan offered by a PDP sponsor that
11 provides for tiered cost-sharing for drugs included
12 within a formulary and provides lower cost-sharing
13 for preferred drugs included within the formulary,
14 an individual who is enrolled in the plan may re-
15 quest coverage of a nonpreferred drug under the
16 terms applicable for preferred drugs if the pre-
17 scribing physician determines that the preferred
18 drug for treatment of the same condition is not as
19 effective for the individual or has adverse effects for
20 the individual.

21 “(f) APPEALS.—

22 “(1) IN GENERAL.—Subject to paragraph (2), a
23 PDP sponsor shall meet the requirements of para-
24 graphs (4) and (5) of section 1852(g) with respect
25 to drugs not included on any formulary in the same

1 manner as such requirements apply to a
2 Medicare+Choice organization with respect to bene-
3 fits it offers under a Medicare+Choice plan under
4 part C.

5 “(2) FORMULARY DETERMINATIONS.—An indi-
6 vidual who is enrolled in a prescription drug plan of-
7 fered by a PDP sponsor may appeal to obtain cov-
8 erage for a covered outpatient drug that is not on
9 a formulary of the sponsor if the prescribing physi-
10 cian determines that the formulary drug for treat-
11 ment of the same condition is not as effective for the
12 individual or has adverse effects for the individual.

13 “(g) CONFIDENTIALITY AND ACCURACY OF EN-
14 ROLLEE RECORDS.—A PDP sponsor shall meet the re-
15 quirements of section 1852(h) with respect to enrollees
16 under this part in the same manner as such requirements
17 apply to a Medicare+Choice organization with respect to
18 enrollees under part C.

19 **“SEC. 1860D. REQUIREMENTS FOR PRESCRIPTION DRUG**
20 **PLAN (PDP) SPONSORS; CONTRACTS; ESTAB-**
21 **LISHMENT OF STANDARDS.**

22 “(a) GENERAL REQUIREMENTS.—Each PDP sponsor
23 of a prescription drug plan shall meet the following re-
24 quirements:

1 “(1) LICENSURE.—Subject to subsection (c),
2 the sponsor is organized and licensed under State
3 law as a risk-bearing entity eligible to offer health
4 insurance or health benefits coverage in each State
5 in which it offers a prescription drug plan.

6 “(2) ASSUMPTION OF FINANCIAL RISK.—

7 “(A) IN GENERAL.—Subject to subpara-
8 graph (B) and section 1860E(d)(2), the entity
9 assumes full financial risk on a prospective
10 basis for qualified prescription drug coverage
11 that it offers under a prescription drug plan
12 and that is not covered under section 1860H.

13 “(B) REINSURANCE PERMITTED.—The en-
14 tity may obtain insurance or make other ar-
15 rangements for the cost of coverage provided to
16 any enrolled member under this part.

17 “(3) SOLVENCY FOR UNLICENSED SPONSORS.—

18 In the case of a sponsor that is not described in
19 paragraph (1), the sponsor shall meet solvency
20 standards established by the Administrator under
21 subsection (d).

22 “(b) CONTRACT REQUIREMENTS.—

23 “(1) IN GENERAL.—The Administrator shall
24 not permit the election under section 1860A of a
25 prescription drug plan offered by a PDP sponsor

1 under this part, and the sponsor shall not be eligible
2 for payments under section 1860G or 1860H, unless
3 the Administrator has entered into a contract under
4 this subsection with the sponsor with respect to the
5 offering of such plan. Such a contract with a spon-
6 sor may cover more than one prescription drug plan.
7 Such contract shall provide that the sponsor agrees
8 to comply with the applicable requirements and
9 standards of this part and the terms and conditions
10 of payment as provided for in this part.

11 “(2) NEGOTIATION REGARDING TERMS AND
12 CONDITIONS.—The Administrator shall have the
13 same authority to negotiate the terms and conditions
14 of prescription drug plans under this part as the Di-
15 rector of the Office of Personnel Management has
16 with respect to health benefits plans under chapter
17 89 of title 5, United States Code. In negotiating the
18 terms and conditions regarding premiums for which
19 information is submitted under section 1860F(a)(2),
20 the Administrator shall take into account the sub-
21 sidy payments under section 1860H and the ad-
22 justed community rate (as defined in section
23 1854(f)(3)) for the benefits covered.

24 “(3) INCORPORATION OF CERTAIN
25 MEDICARE+CHOICE CONTRACT REQUIREMENTS.—

1 The following provisions of section 1857 shall apply,
2 subject to subsection (c)(5), to contracts under this
3 section in the same manner as they apply to con-
4 tracts under section 1857(a):

5 “(A) MINIMUM ENROLLMENT.—Para-
6 graphs (1) and (3) of section 1857(b).

7 “(B) CONTRACT PERIOD AND EFFECTIVE-
8 NESS.—Paragraphs (1) through (3) and (5) of
9 section 1857(c).

10 “(C) PROTECTIONS AGAINST FRAUD AND
11 BENEFICIARY PROTECTIONS.—Section 1857(d).

12 “(D) ADDITIONAL CONTRACT TERMS.—
13 Section 1857(e); except that in applying section
14 1857(e)(2) under this part—

15 “(i) such section shall be applied sepa-
16 rately to costs relating to this part (from
17 costs under part C);

18 “(ii) in no case shall the amount of
19 the fee established under this subpara-
20 graph for a plan exceed 20 percent of the
21 maximum amount of the fee that may be
22 established under subparagraph (B) of
23 such section; and

1 “(iii) no fees shall be applied under
2 this subparagraph with respect to
3 Medicare+Choice plans.

4 “(E) INTERMEDIATE SANCTIONS.—Section
5 1857(g).

6 “(F) PROCEDURES FOR TERMINATION.—
7 Section 1857(h).

8 “(4) RULES OF APPLICATION FOR INTER-
9 MEDIATE SANCTIONS.—In applying paragraph
10 (3)(E)—

11 “(A) the reference in section
12 1857(g)(1)(B) to section 1854 is deemed a ref-
13 erence to this part; and

14 “(B) the reference in section
15 1857(g)(1)(F) to section 1852(k)(2)(A)(ii) shall
16 not be applied.

17 “(c) WAIVER OF CERTAIN REQUIREMENTS TO EX-
18 PAND CHOICE.—

19 “(1) IN GENERAL.—In the case of an entity
20 that seeks to offer a prescription drug plan in a
21 State, the Administrator shall waive the requirement
22 of subsection (a)(1) that the entity be licensed in
23 that State if the Administrator determines, based on
24 the application and other evidence presented to the
25 Administrator, that any of the grounds for approval

1 of the application described in paragraph (2) has
2 been met.

3 “(2) GROUNDS FOR APPROVAL.—The grounds
4 for approval under this paragraph are the grounds
5 for approval described in subparagraph (B), (C),
6 and (D) of section 1855(a)(2), and also include the
7 application by a State of any grounds other than
8 those required under Federal law.

9 “(3) APPLICATION OF WAIVER PROCEDURES.—
10 With respect to an application for a waiver (or a
11 waiver granted) under this subsection, the provisions
12 of subparagraphs (E), (F), and (G) of section
13 1855(a)(2) shall apply.

14 “(4) LICENSURE DOES NOT SUBSTITUTE FOR
15 OR CONSTITUTE CERTIFICATION.—The fact that an
16 entity is licensed in accordance with subsection
17 (a)(1) does not deem the entity to meet other re-
18 quirements imposed under this part for a PDP spon-
19 sor.

20 “(5) REFERENCES TO CERTAIN PROVISIONS.—
21 For purposes of this subsection, in applying provi-
22 sions of section 1855(a)(2) under this subsection to
23 prescription drug plans and PDP sponsors—

24 “(A) any reference to a waiver application
25 under section 1855 shall be treated as a ref-

1 erence to a waiver application under paragraph
2 (1); and

3 “(B) any reference to solvency standards
4 shall be treated as a reference to solvency
5 standards established under subsection (d).

6 “(d) SOLVENCY STANDARDS FOR NON-LICENSED
7 SPONSORS.—

8 “(1) ESTABLISHMENT.—The Administrator
9 shall establish, by not later than October 1, 2003,
10 financial solvency and capital adequacy standards
11 that an entity that does not meet the requirements
12 of subsection (a)(1) must meet to qualify as a PDP
13 sponsor under this part.

14 “(2) COMPLIANCE WITH STANDARDS.—Each
15 PDP sponsor that is not licensed by a State under
16 subsection (a)(1) and for which a waiver application
17 has been approved under subsection (c) shall meet
18 solvency and capital adequacy standards established
19 under paragraph (1). The Administrator shall estab-
20 lish certification procedures for such PDP sponsors
21 with respect to such solvency standards in the man-
22 ner described in section 1855(c)(2).

23 “(e) OTHER STANDARDS.—The Administrator shall
24 establish by regulation other standards (not described in
25 subsection (d)) for PDP sponsors and plans consistent

1 with, and to carry out, this part. The Administrator shall
2 publish such regulations by October 1, 2003.

3 “(f) RELATION TO STATE LAWS.—

4 “(1) IN GENERAL.—The standards established
5 under this part shall supersede any State law or reg-
6 ulation (other than State licensing laws or State
7 laws relating to plan solvency, except as provided in
8 subsection (d)) with respect to prescription drug
9 plans which are offered by PDP sponsors under this
10 part.

11 “(2) PROHIBITION OF STATE IMPOSITION OF
12 PREMIUM TAXES.—No State may impose a premium
13 tax or similar tax with respect to premiums paid to
14 PDP sponsors for prescription drug plans under this
15 part, or with respect to any payments made to such
16 a sponsor by the Administrator under this part.

17 **“SEC. 1860E. PROCESS FOR BENEFICIARIES TO SELECT**
18 **QUALIFIED PRESCRIPTION DRUG COVERAGE.**

19 “(a) IN GENERAL.—The Administrator shall estab-
20 lish a process for the selection of the prescription drug
21 plan or Medicare+Choice plan which offer qualified pre-
22 scription drug coverage through which eligible individuals
23 elect qualified prescription drug coverage under this part.

24 “(b) ELEMENTS.—Such process shall include the fol-
25 lowing:

1 “(1) Annual, coordinated election periods, in
2 which such individuals can change the qualifying
3 plans through which they obtain coverage, in accord-
4 ance with section 1860A(b)(2).

5 “(2) Active dissemination of information to pro-
6 mote an informed selection among qualifying plans
7 based upon price, quality, and other features, in the
8 manner described in (and in coordination with) sec-
9 tion 1851(d), including the provision of annual com-
10 parative information, maintenance of a toll-free hot-
11 line, and the use of non-Federal entities.

12 “(3) Coordination of elections through filing
13 with a Medicare+Choice organization or a PDP
14 sponsor, in the manner described in (and in coordi-
15 nation with) section 1851(c)(2).

16 “(c) MEDICARE+CHOICE ENROLLEE IN PLAN OF-
17 FERING PRESCRIPTION DRUG COVERAGE MAY ONLY OB-
18 TAIN BENEFITS THROUGH THE PLAN.—An individual
19 who is enrolled under a Medicare+Choice plan that offers
20 qualified prescription drug coverage may only elect to re-
21 ceive qualified prescription drug coverage under this part
22 through such plan.

23 “(d) ASSURING ACCESS TO A CHOICE OF QUALIFIED
24 PRESCRIPTION DRUG COVERAGE.—

1 “(1) CHOICE OF AT LEAST TWO PLANS IN EACH
2 AREA.—

3 “(A) IN GENERAL.—The Administrator
4 shall assure that each individual who is entitled
5 to benefits under part A or enrolled under part
6 B and who is residing in an area in the United
7 States has available, consistent with subpara-
8 graph (B), a choice of enrollment in at least
9 two qualifying plans (as defined in paragraph
10 (5)) in the area in which the individual resides,
11 at least one of which is a prescription drug
12 plan.

13 “(B) REQUIREMENT FOR DIFFERENT
14 PLAN SPONSORS.—The requirement in subpara-
15 graph (A) is not satisfied with respect to an
16 area if only one PDP sponsor or
17 Medicare+Choice organization offers all the
18 qualifying plans in the area.

19 “(2) GUARANTEEING ACCESS TO COVERAGE.—
20 In order to assure access under paragraph (1) and
21 consistent with paragraph (3), the Administrator
22 may provide financial incentives (including partial
23 underwriting of risk) for a PDP sponsor to expand
24 the service area under an existing prescription drug
25 plan to adjoining or additional areas or to establish

1 such a plan (including offering such a plan on a re-
2 gional or nationwide basis), but only so long as (and
3 to the extent) necessary to assure the access guaran-
4 teed under paragraph (1).

5 “(3) LIMITATION ON AUTHORITY.—In exer-
6 cising authority under this subsection, the
7 Administrator—

8 “(A) shall not provide for the full under-
9 writing of financial risk for any PDP sponsor;

10 “(B) shall not provide for any under-
11 writing of financial risk for a public PDP spon-
12 sor with respect to the offering of a nationwide
13 prescription drug plan; and

14 “(C) shall seek to maximize the assump-
15 tion of financial risk by PDP sponsors or
16 Medicare+Choice organizations.

17 “(4) REPORTS.—The Administrator shall, in
18 each annual report to Congress under section
19 1808(f), include information on the exercise of au-
20 thority under this subsection. The Administrator
21 also shall include such recommendations as may be
22 appropriate to minimize the exercise of such author-
23 ity, including minimizing the assumption of financial
24 risk.

1 “(5) QUALIFYING PLAN DEFINED.—For pur-
 2 poses of this subsection, the term ‘qualifying plan’
 3 means a prescription drug plan or a
 4 Medicare+Choice plan that includes qualified pre-
 5 scription drug coverage.

6 **“SEC. 1860F. SUBMISSION OF BIDS.**

7 “(a) SUBMISSION OF BIDS AND RELATED INFORMA-
 8 TION.—

9 “(1) IN GENERAL.—Each PDP sponsor shall
 10 submit to the Administrator information of the type
 11 described in paragraph (2) in the same manner as
 12 information is submitted by a Medicare+Choice or-
 13 ganization under section 1854(a)(1).

14 “(2) TYPE OF INFORMATION.—The information
 15 described in this paragraph is the following:

16 “(A) Information on the qualified prescrip-
 17 tion drug coverage to be provided.

18 “(B) Information on the actuarial value of
 19 the coverage.

20 “(C) Information on the bid for the cov-
 21 erage, including an actuarial certification of—

22 “(i) the actuarial basis for such bid;

23 “(ii) the portion of such bid attrib-
 24 utable to benefits in excess of standard
 25 coverage; and

1 “(iii) the reduction in such bid result-
2 ing from the subsidy payments provided
3 under section 1860H.

4 “(D) Such other information as the Ad-
5 ministrator may require to carry out this part.

6 “(3) REVIEW.—The Administrator shall review
7 the information filed under paragraph (2) for the
8 purpose of conducting negotiations under section
9 1860D(b)(2).

10 “(b) UNIFORM BID.—

11 “(1) IN GENERAL.—The bid for a prescription
12 drug plan under this section may not vary among in-
13 dividuals enrolled in the plan in the same service
14 area.

15 “(2) CONSTRUCTION.—Nothing in paragraph
16 (1) shall be construed as preventing the imposition
17 of a late enrollment penalty under section
18 1860A(c)(2)(B).

19 “(c) COLLECTION.—

20 “(1) USE OF ELECTRONIC FUNDS TRANSFER
21 MECHANISM OR, AT BENEFICIARY’S OPTION, WITH-
22 HOLDING FROM SOCIAL SECURITY PAYMENT.—In ac-
23 cordance with regulations, a PDP sponsor may en-
24 courage that enrollees under a plan make payment
25 of the premium established by the plan under this

1 part through an electronic funds transfer mecha-
2 nism, such as automatic charges of an account at a
3 financial institution or a credit or debit card ac-
4 count, or, at the option of an enrollee, through with-
5 holding from benefit payments in the manner pro-
6 vided under section 1840 with respect to monthly
7 premiums under section 1839. All such amounts
8 shall be credited to the Medicare Prescription Drug
9 Trust Fund.

10 “(2) OFFSETTING.—Reductions in premiums
11 for coverage under parts A and B as a result of a
12 selection of a Medicare+Choice plan may be used to
13 reduce the premium otherwise imposed under para-
14 graph (1).

15 “(3) PAYMENT OF PLANS.—PDP plans shall re-
16 ceive payment based on bid amounts in the same
17 manner as Medicare+Choice organizations receive
18 payment based on bid amounts under section
19 1853(a)(1)(A)(ii) except that such payment shall be
20 made from the Medicare Prescription Drug Trust
21 Fund.

22 “(d) ACCEPTANCE OF BENCHMARK AMOUNT AS
23 FULL PREMIUM FOR SUBSIDIZED LOW-INCOME INDIVID-
24 UALS IF NO STANDARD (OR EQUIVALENT) COVERAGE IN
25 AN AREA.—

1 “(1) IN GENERAL.—If there is no standard pre-
 2 scription drug coverage (as defined in paragraph
 3 (2)) offered in an area, in the case of an individual
 4 who is eligible for a premium subsidy under section
 5 1860G and resides in the area, the PDP sponsor of
 6 any prescription drug plan offered in the area (and
 7 any Medicare+Choice organization that offers quali-
 8 fied prescription drug coverage in the area) shall ac-
 9 cept the benchmark bid amount (under section
 10 1860G(b)(2)) as payment in full for the premium
 11 charge for qualified prescription drug coverage.

12 “(2) STANDARD PRESCRIPTION DRUG COV-
 13 ERAGE DEFINED.—For purposes of this subsection,
 14 the term ‘standard prescription drug coverage’
 15 means qualified prescription drug coverage that is
 16 standard coverage or that has an actuarial value
 17 equivalent to the actuarial value for standard cov-
 18 erage.

19 **“SEC. 1860G. PREMIUM AND COST-SHARING SUBSIDIES FOR**
 20 **LOW-INCOME INDIVIDUALS.**

21 “(a) INCOME-RELATED SUBSIDIES FOR INDIVIDUALS
 22 WITH INCOME BELOW 150 PERCENT OF FEDERAL POV-
 23 ERTY LEVEL.—

24 “(1) FULL PREMIUM SUBSIDY AND REDUCTION
 25 OF COST-SHARING FOR INDIVIDUALS WITH INCOME

1 BELOW 150 PERCENT OF FEDERAL POVERTY
2 LEVEL.—In the case of a subsidy eligible individual
3 (as defined in paragraph (4)) who is determined to
4 have income that does not exceed 150 percent of the
5 Federal poverty level, the individual is entitled under
6 this section—

7 “(A) to an income-related premium subsidy
8 equal to 100 percent of the amount described in
9 subsection (b)(1); and

10 “(B) subject to subsection (c), to the sub-
11 stitution for the beneficiary cost-sharing de-
12 scribed in paragraphs (1) and (2) of section
13 1860B(b) (up to the initial coverage limit speci-
14 fied in paragraph (3) of such section) of
15 amounts that do not exceed \$2 for a multiple
16 source or generic drug (as described in section
17 1927(k)(7)(A)) and \$5 for a non-preferred
18 drug.

19 “(2) SLIDING SCALE PREMIUM SUBSIDY AND
20 REDUCTION OF COST-SHARING FOR INDIVIDUALS
21 WITH INCOME ABOVE 150, BUT BELOW 175 PERCENT,
22 OF FEDERAL POVERTY LEVEL.—In the case of a
23 subsidy eligible individual who is determined to have
24 income that exceeds 150 percent, but does not ex-

1 ceed 175 percent, of the Federal poverty level, the
2 individual is entitled under this section to—

3 “(A) an income-related premium subsidy
4 determined on a linear sliding scale ranging
5 from 100 percent of the amount described in
6 subsection (b)(1) for individuals with incomes
7 at 150 percent of such level to 0 percent of
8 such amount for individuals with incomes at
9 175 percent of such level; and

10 “(B) subject to subsection (c), to the sub-
11 stitution for the beneficiary cost-sharing de-
12 scribed in paragraphs (1) and (2) of section
13 1860B(b) (up to the initial coverage limit speci-
14 fied in paragraph (3) of such section) of
15 amounts that do not exceed \$2 for a multiple
16 source or generic drug (as described in section
17 1927(k)(7)(A)) and \$5 for a non-preferred
18 drug.

19 “(3) CONSTRUCTION.—Nothing in this section
20 shall be construed as preventing a PDP sponsor
21 from reducing to 0 the cost-sharing otherwise appli-
22 cable to generic drugs.

23 “(4) DETERMINATION OF ELIGIBILITY.—

24 “(A) SUBSIDY ELIGIBLE INDIVIDUAL DE-
25 FINED.—For purposes of this section, subject

1 to subparagraph (D), the term ‘subsidy eligible
2 individual’ means an individual who—

3 “(i) is eligible to elect, and has elect-
4 ed, to obtain qualified prescription drug
5 coverage under this part;

6 “(ii) has income below 175 percent of
7 the Federal poverty line; and

8 “(iii) meets the resources requirement
9 described in section 1905(p)(1)(C).

10 “(B) DETERMINATIONS.—The determina-
11 tion of whether an individual residing in a State
12 is a subsidy eligible individual and the amount
13 of such individual’s income shall be determined
14 under the State medicaid plan for the State
15 under section 1935(a). In the case of a State
16 that does not operate such a medicaid plan (ei-
17 ther under title XIX or under a statewide waiv-
18 er granted under section 1115), such deter-
19 mination shall be made under arrangements
20 made by the Administrator.

21 “(C) INCOME DETERMINATIONS.—For pur-
22 poses of applying this section—

23 “(i) income shall be determined in the
24 manner described in section
25 1905(p)(1)(B); and

1 “(ii) the term ‘Federal poverty line’
2 means the official poverty line (as defined
3 by the Office of Management and Budget,
4 and revised annually in accordance with
5 section 673(2) of the Omnibus Budget
6 Reconciliation Act of 1981) applicable to a
7 family of the size involved.

8 “(D) TREATMENT OF TERRITORIAL RESI-
9 DENTS.—In the case of an individual who is not
10 a resident of the 50 States or the District of
11 Columbia, the individual is not eligible to be a
12 subsidy eligible individual but may be eligible
13 for financial assistance with prescription drug
14 expenses under section 1935(e).

15 “(E) TREATMENT OF CONFORMING
16 MEDIGAP POLICIES.—For purposes of this sec-
17 tion, the term ‘qualified prescription drug cov-
18 erage’ includes a medicare supplemental policy
19 described in section 1860H(b)(4).

20 “(5) INDEXING DOLLAR AMOUNTS.—

21 “(A) FOR 2006.—The dollar amounts ap-
22 plied under paragraphs (1)(B) and (2)(B) for
23 2006 shall be the dollar amounts specified in
24 such paragraph increased by the annual per-

1 centage increase described in section
2 1860B(b)(5) for 2006.

3 “(B) FOR SUBSEQUENT YEARS.—The dol-
4 lar amounts applied under paragraphs (1)(B)
5 and (2)(B) for a year after 2006 shall be the
6 amounts (under this paragraph) applied under
7 paragraph (1)(B) or (2)(B) for the preceding
8 year increased by the annual percentage in-
9 crease described in section 1860B(b)(5) (relat-
10 ing to growth in medicare prescription drug
11 costs per beneficiary) for the year involved.

12 “(b) PREMIUM SUBSIDY AMOUNT.—

13 “(1) IN GENERAL.—The premium subsidy
14 amount described in this subsection for an individual
15 residing in an area is the benchmark bid amount (as
16 defined in paragraph (2)) for qualified prescription
17 drug coverage offered by the prescription drug plan
18 or the Medicare+Choice plan in which the individual
19 is enrolled.

20 “(2) BENCHMARK BID AMOUNT DEFINED.—For
21 purposes of this subsection, the term ‘benchmark bid
22 amount’ means, with respect to qualified prescrip-
23 tion drug coverage offered under—

24 “(A) a prescription drug plan that—

1 “(i) provides standard coverage (or al-
 2 ternative prescription drug coverage the
 3 actuarial value is equivalent to that of
 4 standard coverage), the bid amount for en-
 5 rollment under the plan under this part
 6 (determined without regard to any subsidy
 7 under this section or any late enrollment
 8 penalty under section 1860A(c)(2)(B)); or

9 “(ii) provides alternative prescription
 10 drug coverage the actuarial value of which
 11 is greater than that of standard coverage,
 12 the bid amount described in clause (i) mul-
 13 tiplied by the ratio of (I) the actuarial
 14 value of standard coverage, to (II) the ac-
 15 tuarial value of the alternative coverage; or

16 “(B) a Medicare+Choice plan, the portion
 17 of the bid amount that is attributable to statu-
 18 tory drug benefits (described in section
 19 1853(a)(1)(A)(ii)(II)).

20 “(c) RULES IN APPLYING COST-SHARING SUB-
 21 SIDIES.—

22 “(1) IN GENERAL.—In applying subsections
 23 (a)(1)(B) and (a)(2)(B), nothing in this part shall
 24 be construed as preventing a plan or provider from

1 waiving or reducing the amount of cost-sharing oth-
2 erwise applicable.

3 “(2) LIMITATION ON CHARGES.—In the case of
4 an individual receiving cost-sharing subsidies under
5 subsection (a)(1)(B) or (a)(2)(B), the PDP sponsor
6 may not charge more than \$5 per prescription.

7 “(3) APPLICATION OF INDEXING RULES.—The
8 provisions of subsection (a)(4) shall apply to the dol-
9 lar amount specified in paragraph (2) in the same
10 manner as they apply to the dollar amounts specified
11 in subsections (a)(1)(B) and (a)(2)(B).

12 “(d) ADMINISTRATION OF SUBSIDY PROGRAM.—The
13 Administrator shall provide a process whereby, in the case
14 of an individual who is determined to be a subsidy eligible
15 individual and who is enrolled in prescription drug plan
16 or is enrolled in a Medicare+Choice plan under which
17 qualified prescription drug coverage is provided—

18 “(1) the Administrator provides for a notifica-
19 tion of the PDP sponsor or Medicare+Choice orga-
20 nization involved that the individual is eligible for a
21 subsidy and the amount of the subsidy under sub-
22 section (a);

23 “(2) the sponsor or organization involved re-
24 duces the premiums or cost-sharing otherwise im-
25 posed by the amount of the applicable subsidy and

1 submits to the Administrator information on the
2 amount of such reduction; and

3 “(3) the Administrator periodically and on a
4 timely basis reimburses the sponsor or organization
5 for the amount of such reductions.

6 The reimbursement under paragraph (3) with respect to
7 cost-sharing subsidies may be computed on a capitated
8 basis, taking into account the actuarial value of the sub-
9 sidies and with appropriate adjustments to reflect dif-
10 ferences in the risks actually involved.

11 “(e) RELATION TO MEDICAID PROGRAM.—

12 “(1) IN GENERAL.—For provisions providing
13 for eligibility determinations, and additional financ-
14 ing, under the medicaid program, see section 1935.

15 “(2) MEDICAID PROVIDING WRAP AROUND BEN-
16 EFITS.—The coverage provided under this part is
17 primary payor to benefits for prescribed drugs pro-
18 vided under the medicaid program under title XIX.

19 “(3) COORDINATION.—The Administrator shall
20 develop and implement a plan for the coordination
21 of prescription drug benefits under this part with
22 the benefits provided under the medicaid program
23 under title XIX, with particular attention to insur-
24 ing coordination of payments and prevention of
25 fraud and abuse. In developing and implementing

1 such plan, the Administrator shall involve the Sec-
2 retary, the States, the data processing industry,
3 pharmacists, and pharmaceutical manufacturers,
4 and other experts.

5 **“SEC. 1860H. SUBSIDIES FOR ALL MEDICARE BENE-**
6 **FICIARIES FOR QUALIFIED PRESCRIPTION**
7 **DRUG COVERAGE.**

8 “(a) SUBSIDY PAYMENT.—In order to reduce pre-
9 mium levels applicable to qualified prescription drug cov-
10 erage for all medicare beneficiaries consistent with an
11 overall subsidy level of 66 percent, to reduce adverse selec-
12 tion among prescription drug plans and Medicare+Choice
13 plans that provide qualified prescription drug coverage,
14 and to promote the participation of PDP sponsors under
15 this part, the Administrator shall provide in accordance
16 with this section for payment to a qualifying entity (as
17 defined in subsection (b)) of the following subsidies:

18 “(1) DIRECT SUBSIDY.—In the case of an indi-
19 vidual enrolled in a prescription drug plan,
20 Medicare+Choice plan that provides qualified pre-
21 scription drug coverage, or qualified retiree prescrip-
22 tion drug plan, a direct subsidy equal to 36 percent
23 of the total payments made by a qualifying entity
24 for standard drug coverage provided under the re-
25 spective plan.

1 “(2) SUBSIDY THROUGH REINSURANCE.—The
2 reinsurance payment amount (as defined in sub-
3 section (c)), which in the aggregate is 30 percent of
4 such total payments, for excess costs incurred in
5 providing qualified prescription drug coverage—

6 “(A) for individuals enrolled with a pre-
7 scription drug plan under this part;

8 “(B) for individuals enrolled with a
9 Medicare+Choice plan that provides qualified
10 prescription drug coverage under part C; and

11 “(C) for individuals who are enrolled in a
12 qualified retiree prescription drug plan.

13 This section constitutes budget authority in advance of ap-
14 propriations Acts and represents the obligation of the Ad-
15 ministrator to provide for the payment of amounts pro-
16 vided under this section.

17 “(b) QUALIFYING ENTITY DEFINED.—For purposes
18 of this section, the term ‘qualifying entity’ means any of
19 the following that has entered into an agreement with the
20 Administrator to provide the Administrator with such in-
21 formation as may be required to carry out this section:

22 “(1) A PDP sponsor offering a prescription
23 drug plan under this part.

1 “(2) A Medicare+Choice organization that pro-
2 vides qualified prescription drug coverage under a
3 Medicare+Choice plan under part C.

4 “(3) The sponsor of a qualified retiree prescrip-
5 tion drug plan (as defined in subsection (f)).

6 “(c) REINSURANCE PAYMENT AMOUNT.—

7 “(1) IN GENERAL.—Subject to subsection
8 (d)(2) and paragraph (4), the reinsurance payment
9 amount under this subsection for a qualifying cov-
10 ered individual (as defined in subsection (g)(1)) for
11 a coverage year (as defined in subsection (g)(2)) is
12 equal to the sum of the following:

13 “(A) For the portion of the individual’s
14 gross covered prescription drug costs (as de-
15 fined in paragraph (3)) for the year that ex-
16 ceeds the initial copayment threshold specified
17 in section 1860B(b)(2)(C), but does not exceed
18 the initial coverage limit specified in section
19 1860B(b)(3), an amount equal to 30 percent of
20 the allowable costs (as defined in paragraph
21 (2)) attributable to such gross covered prescrip-
22 tion drug costs.

23 “(B) For the portion of the individual’s
24 gross covered prescription drug costs for the
25 year that exceeds the annual out-of-pocket

1 threshold specified in 1860B(b)(4)(B), an
2 amount equal to 80 percent of the allowable
3 costs attributable to such gross covered pre-
4 scription drug costs.

5 “(2) ALLOWABLE COSTS.—For purposes of this
6 section, the term ‘allowable costs’ means, with re-
7 spect to gross covered prescription drug costs under
8 a plan described in subsection (b) offered by a quali-
9 fying entity, the part of such costs that are actually
10 paid (net of average percentage rebates) under the
11 plan, but in no case more than the part of such
12 costs that would have been paid under the plan if
13 the prescription drug coverage under the plan were
14 standard coverage.

15 “(3) GROSS COVERED PRESCRIPTION DRUG
16 COSTS.—For purposes of this section, the term
17 ‘gross covered prescription drug costs’ means, with
18 respect to an enrollee with a qualifying entity under
19 a plan described in subsection (b) during a coverage
20 year, the costs incurred under the plan (including
21 costs attributable to administrative costs) for cov-
22 ered prescription drugs dispensed during the year,
23 including costs relating to the deductible, whether
24 paid by the enrollee or under the plan, regardless of
25 whether the coverage under the plan exceeds stand-

1 ard coverage and regardless of when the payment
2 for such drugs is made.

3 “(4) INDEXING DOLLAR AMOUNTS.—

4 “(A) AMOUNTS FOR 2005.—The dollar
5 amounts applied under paragraph (1) for 2005
6 shall be the dollar amounts specified in such
7 paragraph.

8 “(B) FOR 2006.—The dollar amounts ap-
9 plied under paragraph (1) for 2006 shall be the
10 dollar amounts specified in such paragraph in-
11 creased by the annual percentage increase de-
12 scribed in section 1860B(b)(5) for 2006.

13 “(C) FOR SUBSEQUENT YEARS.—The dol-
14 lar amounts applied under paragraph (1) for a
15 year after 2006 shall be the amounts (under
16 this paragraph) applied under paragraph (1)
17 for the preceding year increased by the annual
18 percentage increase described in section
19 1860B(b)(5) (relating to growth in medicare
20 prescription drug costs per beneficiary) for the
21 year involved.

22 “(D) ROUNDING.—Any amount, deter-
23 mined under the preceding provisions of this
24 paragraph for a year, which is not a multiple of

1 \$10 shall be rounded to the nearest multiple of
2 \$10.

3 “(d) ADJUSTMENT OF PAYMENTS.—

4 “ (1) ADJUSTMENT OF REINSURANCE PAY-
5 MENTS TO ASSURE 30 PERCENT LEVEL OF SUBSIDY
6 THROUGH REINSURANCE.—

7 “(A) ESTIMATION OF PAYMENTS.—The
8 Administrator shall estimate—

9 “ (i) the total payments to be made
10 (without regard to this subsection) during
11 a year under subsections (a)(2) and (c);
12 and

13 “ (ii) the total payments to be made by
14 qualifying entities for standard coverage
15 under plans described in subsection (b)
16 during the year.

17 “(B) ADJUSTMENT.—The Administrator
18 shall proportionally adjust the payments made
19 under subsections (a)(2) and (c) for a coverage
20 year in such manner so that the total of the
21 payments made under such subsections for the
22 year is equal to 30 percent of the total pay-
23 ments described in subparagraph (A)(ii).

24 “(2) RISK ADJUSTMENT FOR DIRECT SUB-
25 SIDIES.—To the extent the Administrator deter-

1 mines it appropriate to avoid risk selection, the pay-
2 ments made for direct subsidies under subsection
3 (a)(1) are subject to adjustment based upon risk
4 factors specified by the Administrator. Any such risk
5 adjustment shall be designed in a manner as to not
6 result in a change in the aggregate payments made
7 under such subsection.

8 “(e) PAYMENT METHODS.—

9 “(1) IN GENERAL.—Payments under this sec-
10 tion shall be based on such a method as the Admin-
11 istrator determines. The Administrator may estab-
12 lish a payment method by which interim payments
13 of amounts under this section are made during a
14 year based on the Administrator’s best estimate of
15 amounts that will be payable after obtaining all of
16 the information.

17 “(2) SOURCE OF PAYMENTS.—Payments under
18 this section shall be made from the Medicare Pre-
19 scription Drug Trust Fund.

20 “(f) QUALIFIED RETIREE PRESCRIPTION DRUG
21 PLAN DEFINED.—

22 “(1) IN GENERAL.—For purposes of this sec-
23 tion, the term ‘qualified retiree prescription drug
24 plan’ means employment-based retiree health cov-
25 erage (as defined in paragraph (3)(A)) if, with re-

1 spect to an individual enrolled (or eligible to be en-
2 rolled) under this part who is covered under the
3 plan, the following requirements are met:

4 “(A) ASSURANCE.—The sponsor of the
5 plan shall annually attest, and provide such as-
6 surances as the Administrator may require,
7 that the coverage meets or exceeds the require-
8 ments for qualified prescription drug coverage.

9 “(B) AUDITS.—The sponsor (and the plan)
10 shall maintain, and afford the Administrator
11 access to, such records as the Administrator
12 may require for purposes of audits and other
13 oversight activities necessary to ensure the ade-
14 quacy of prescription drug coverage, and the ac-
15 curacy of payments made.

16 “(C) PROVISION OF CERTIFICATION OF
17 PRESCRIPTION DRUG COVERAGE.—The sponsor
18 of the plan shall provide for issuance of certifi-
19 cations of the type described in section
20 1860A(c)(2)(D).

21 “(2) LIMITATION ON BENEFIT ELIGIBILITY.—
22 No payment shall be provided under this section
23 with respect to an individual who is enrolled under
24 a qualified retiree prescription drug plan unless the
25 individual is—

1 “(A) enrolled under this part;

2 “(B) is covered under the plan; and

3 “(C) is eligible to obtain qualified prescrip-
4 tion drug coverage under section 1860A but did
5 not elect such coverage under this part (either
6 through a prescription drug plan or through a
7 Medicare+Choice plan).

8 “(3) DEFINITIONS.—As used in this section:

9 “(A) EMPLOYMENT-BASED RETIREE
10 HEALTH COVERAGE.—The term ‘employment-
11 based retiree health coverage’ means health in-
12 surance or other coverage of health care costs
13 for individuals enrolled under this part (or for
14 such individuals and their spouses and depend-
15 ents) based on their status as former employees
16 or labor union members.

17 “(B) SPONSOR.—The term ‘sponsor’
18 means a plan sponsor, as defined in section
19 3(16)(B) of the Employee Retirement Income
20 Security Act of 1974.

21 “(g) GENERAL DEFINITIONS.—For purposes of this
22 section:

23 “(1) QUALIFYING COVERED INDIVIDUAL.—The
24 term ‘qualifying covered individual’ means an indi-
25 vidual who—

1 “(A) is enrolled with a prescription drug
2 plan under this part;

3 “(B) is enrolled with a Medicare+Choice
4 plan that provides qualified prescription drug
5 coverage under part C; or

6 “(C) is enrolled for benefits under this title
7 and is covered under a qualified retiree pre-
8 scription drug plan.

9 “(2) COVERAGE YEAR.—The term ‘coverage
10 year’ means a calendar year in which covered out-
11 patient drugs are dispensed if a claim for payment
12 is made under the plan for such drugs, regardless of
13 when the claim is paid.

14 **“SEC. 1860I. MEDICARE PRESCRIPTION DRUG TRUST FUND.**

15 “(a) IN GENERAL.—There is created on the books
16 of the Treasury of the United States a trust fund to be
17 known as the ‘Medicare Prescription Drug Trust Fund’
18 (in this section referred to as the ‘Trust Fund’). The
19 Trust Fund shall consist of such gifts and bequests as
20 may be made as provided in section 201(i)(1), and such
21 amounts as may be deposited in, or appropriated to, such
22 fund as provided in this part. Except as otherwise pro-
23 vided in this section, the provisions of subsections (b)
24 through (i) of section 1841 shall apply to the Trust Fund
25 in the same manner as they apply to the Federal Supple-

1 mentary Medical Insurance Trust Fund under such sec-
2 tion.

3 “(b) PAYMENTS FROM TRUST FUND.—

4 “(1) IN GENERAL.—The Managing Trustee
5 shall pay from time to time from the Trust Fund
6 such amounts as the Administrator certifies are nec-
7 essary to make—

8 “(A) payments under section 1860G (relat-
9 ing to low-income subsidy payments);

10 “(B) payments under section 1860H (re-
11 lating to subsidy payments); and

12 “(C) payments with respect to administra-
13 tive expenses under this part in accordance with
14 section 201(g).

15 “(2) TRANSFERS TO MEDICAID ACCOUNT FOR
16 INCREASED ADMINISTRATIVE COSTS.—The Man-
17 aging Trustee shall transfer from time to time from
18 the Trust Fund to the Grants to States for Medicaid
19 account amounts the Administrator certifies are at-
20 tributable to increases in payment resulting from the
21 application of a higher Federal matching percentage
22 under section 1935(b).

23 “(c) DEPOSITS INTO TRUST FUND.—

24 “(1) LOW-INCOME TRANSFER.—There is hereby
25 transferred to the Trust Fund, from amounts appro-

1 priated for Grants to States for Medicaid, amounts
 2 equivalent to the aggregate amount of the reductions
 3 in payments under section 1903(a)(1) attributable to
 4 the application of section 1935(c).

5 “(2) APPROPRIATIONS TO COVER GOVERNMENT
 6 CONTRIBUTIONS.—There are authorized to be appro-
 7 priated from time to time, out of any moneys in the
 8 Treasury not otherwise appropriated, to the Trust
 9 Fund, an amount equivalent to the amount of pay-
 10 ments made from the Trust Fund under subsection
 11 (b), reduced by the amount transferred to the Trust
 12 Fund under paragraph (1).

13 “(d) RELATION TO SOLVENCY REQUIREMENTS.—
 14 Any provision of law that relates to the solvency of the
 15 Trust Fund under this part shall take into account the
 16 Trust Fund and amounts receivable by, or payable from,
 17 the Trust Fund.

18 **“SEC. 1860J. DEFINITIONS; TREATMENT OF REFERENCES**
 19 **TO PROVISIONS IN PART C.**

20 “(a) DEFINITIONS.—For purposes of this part:

21 “(1) COVERED OUTPATIENT DRUGS.—The term
 22 ‘covered outpatient drugs’ is defined in section
 23 1860B(f).

24 “(2) INITIAL COVERAGE LIMIT.—The term ‘ini-
 25 tial coverage limit’ means such limit as established

1 under section 1860B(b)(3), or, in the case of cov-
2 erage that is not standard coverage, the comparable
3 limit (if any) established under the coverage.

4 “(3) MEDICARE PRESCRIPTION DRUG TRUST
5 FUND.—The term ‘Medicare Prescription Drug
6 Trust Fund’ means the Trust Fund created under
7 section 1860I(a).

8 “(4) PDP SPONSOR.—The term ‘PDP sponsor’
9 means an entity that is certified under this part as
10 meeting the requirements and standards of this part
11 for such a sponsor.

12 “(5) PRESCRIPTION DRUG PLAN.—The term
13 ‘prescription drug plan’ means health benefits cov-
14 erage that—

15 “(A) is offered under a policy, contract, or
16 plan by a PDP sponsor pursuant to, and in ac-
17 cordance with, a contract between the Adminis-
18 trator and the sponsor under section 1860D(b);

19 “(B) provides qualified prescription drug
20 coverage; and

21 “(C) meets the applicable requirements of
22 the section 1860C for a prescription drug plan.

23 “(6) QUALIFIED PRESCRIPTION DRUG COV-
24 ERAGE.—The term ‘qualified prescription drug cov-
25 erage’ is defined in section 1860B(a).

1 “(7) STANDARD COVERAGE.—The term ‘stand-
2 ard coverage’ is defined in section 1860B(b).

3 “(b) APPLICATION OF MEDICARE+CHOICE PROVI-
4 SIONS UNDER THIS PART.—For purposes of applying pro-
5 visions of part C under this part with respect to a pre-
6 scription drug plan and a PDP sponsor, unless otherwise
7 provided in this part such provisions shall be applied as
8 if—

9 “(1) any reference to a Medicare+Choice plan
10 included a reference to a prescription drug plan;

11 “(2) any reference to a provider-sponsored or-
12 ganization included a reference to a PDP sponsor;

13 “(3) any reference to a contract under section
14 1857 included a reference to a contract under sec-
15 tion 1860D(b); and

16 “(4) any reference to part C included a ref-
17 erence to this part.”.

18 (b) ADDITIONAL CONFORMING CHANGES.—

19 (1) CONFORMING REFERENCES TO PREVIOUS
20 PART D.—Any reference in law (in effect before the
21 date of the enactment of this Act) to part D of title
22 XVIII of the Social Security Act is deemed a ref-
23 erence to part E of such title (as in effect after such
24 date).

1 (2) CONFORMING AMENDMENT PERMITTING
2 WAIVER OF COST-SHARING.—Section 1128B(b)(3)
3 (42 U.S.C. 1320a–7b(b)(3)) is amended—

4 (A) by striking “and” at the end of sub-
5 paragraph (E);

6 (B) by striking the period at the end of
7 subparagraph (F) and inserting “; and”; and

8 (C) by adding at the end the following new
9 subparagraph:

10 “(G) the waiver or reduction of any cost-shar-
11 ing imposed under part D of title XVIII.”.

12 (3) SUBMISSION OF LEGISLATIVE PROPOSAL.—

13 Not later than 6 months after the date of the enact-
14 ment of this Act, the Secretary of Health and
15 Human Services shall submit to the appropriate
16 committees of Congress a legislative proposal pro-
17 viding for such technical and conforming amend-
18 ments in the law as are required by the provisions
19 of this subtitle.

20 (c) STUDY ON TRANSITIONING PART B PRESCRIP-
21 TION DRUG COVERAGE.—Not later than January 1, 2004,
22 the Medicare Benefits Administrator shall submit a report
23 to Congress that makes recommendations regarding meth-
24 ods for providing benefits under part D of title XVIII of

1 the Social Security Act for outpatient prescription drugs
2 for which benefits are provided under part B of such title.

3 **SEC. 102. OFFERING OF QUALIFIED PRESCRIPTION DRUG**
4 **COVERAGE UNDER THE MEDICARE+CHOICE**
5 **PROGRAM.**

6 (a) IN GENERAL.—Section 1851 (42 U.S.C. 1395w–
7 21) is amended by adding at the end the following new
8 subsection:

9 “(j) AVAILABILITY OF PRESCRIPTION DRUG BENE-
10 FITS.—

11 “(1) OFFER OF QUALIFIED PRESCRIPTION
12 DRUG COVERAGE.—

13 “(A) IN GENERAL.—A Medicare+Choice
14 organization may not offer prescription drug
15 coverage (other than that required under parts
16 A and B) to an enrollee under a
17 Medicare+Choice plan unless such drug cov-
18 erage is at least qualified prescription drug cov-
19 erage and unless the requirements of this sub-
20 section with respect to such coverage are met.

21 “(B) CONSTRUCTION.—Nothing in this
22 subsection shall be construed as—

23 “(i) requiring a Medicare+Choice
24 plan to include coverage of qualified pre-
25 scription drug coverage; or

1 “(ii) permitting a Medicare+Choice
2 organization from providing such coverage
3 to an individual who has not elected such
4 coverage under section 1860A(b).

5 For purposes of this part, an individual who
6 has not elected qualified prescription drug cov-
7 erage under section 1860A(b) shall be treated
8 as being ineligible to enroll in a
9 Medicare+Choice plan under this part that of-
10 fers such coverage.

11 “(2) COMPLIANCE WITH ADDITIONAL BENE-
12 FICIARY PROTECTIONS.—With respect to the offer-
13 ing of qualified prescription drug coverage by a
14 Medicare+Choice organization under a
15 Medicare+Choice plan, the organization and plan
16 shall meet the requirements of section 1860C, in-
17 cluding requirements relating to information dis-
18 semination and grievance and appeals, in the same
19 manner as they apply to a PDP sponsor and a pre-
20 scription drug plan under part D and shall submit
21 to the Administrator the information described in
22 section 1860F(a)(2). The Administrator shall waive
23 such requirements to the extent the Administrator
24 determines that such requirements duplicate require-

1 ments otherwise applicable to the organization or
2 plan under this part.

3 “(3) AVAILABILITY OF PREMIUM AND COST-
4 SHARING SUBSIDIES FOR LOW-INCOME ENROLLEES
5 AND DIRECT AND REINSURANCE SUBSIDY PAYMENTS
6 FOR ORGANIZATIONS.—For provisions—

7 “(A) providing premium and cost-sharing
8 subsidies to low-income individuals receiving
9 qualified prescription drug coverage through a
10 Medicare+Choice plan, see section 1860G; and

11 “(B) providing a Medicare+Choice organi-
12 zation with direct and insurance subsidy pay-
13 ments for providing qualified prescription drug
14 coverage under this part, see section 1860H.

15 “(4) TRANSITION IN INITIAL ENROLLMENT PE-
16 RIOD.—Notwithstanding any other provision of this
17 part, the annual, coordinated election period under
18 subsection (e)(3)(B) for 2005 shall be the 6-month
19 period beginning with November 2004.

20 “(5) QUALIFIED PRESCRIPTION DRUG COV-
21 ERAGE; STANDARD COVERAGE.—For purposes of
22 this part, the terms ‘qualified prescription drug cov-
23 erage’ and ‘standard coverage’ have the meanings
24 given such terms in section 1860B.”.

1 (b) CONFORMING AMENDMENTS.—Section 1851 (42
2 U.S.C. 1395w–21) is amended—

3 (1) in subsection (a)(1)—

4 (A) by inserting “(other than qualified pre-
5 scription drug benefits)” after “benefits”;

6 (B) by striking the period at the end of
7 subparagraph (B) and inserting a comma; and

8 (C) by adding after and below subpara-
9 graph (B) the following:

10 “and may elect qualified prescription drug coverage
11 in accordance with section 1860A.”; and

12 (2) in subsection (g)(1), by inserting “and sec-
13 tion 1860A(c)(2)(B)” after “in this subsection”.

14 (c) EFFECTIVE DATE.—The amendments made by
15 this section apply to coverage provided on or after January
16 1, 2005.

17 **SEC. 103. MEDICAID AMENDMENTS.**

18 (a) DETERMINATIONS OF ELIGIBILITY FOR LOW-IN-
19 COME SUBSIDIES.—

20 (1) REQUIREMENT.—Section 1902(a) (42
21 U.S.C. 1396a(a)) is amended—

22 (A) by striking “and” at the end of para-
23 graph (64);

24 (B) by striking the period at the end of
25 paragraph (65) and inserting “; and”; and

1 (C) by inserting after paragraph (65) the
 2 following new paragraph:

3 “(66) provide for making eligibility determina-
 4 tions under section 1935(a).”.

5 (2) NEW SECTION.—Title XIX is further
 6 amended—

7 (A) by redesignating section 1935 as sec-
 8 tion 1936; and

9 (B) by inserting after section 1934 the fol-
 10 lowing new section:

11 “SPECIAL PROVISIONS RELATING TO MEDICARE
 12 PRESCRIPTION DRUG BENEFIT

13 “SEC. 1935. (a) REQUIREMENT FOR MAKING ELIGI-
 14 BILITY DETERMINATIONS FOR LOW-INCOME SUB-
 15 SIDIES.—As a condition of its State plan under this title
 16 under section 1902(a)(66) and receipt of any Federal fi-
 17 nancial assistance under section 1903(a), a State shall—

18 “(1) make determinations of eligibility for pre-
 19 mium and cost-sharing subsidies under (and in ac-
 20 cordance with) section 1860G;

21 “(2) inform the Administrator of the Medicare
 22 Benefits Administration of such determinations in
 23 cases in which such eligibility is established; and

24 “(3) otherwise provide such Administrator with
 25 such information as may be required to carry out
 26 part D of title XVIII (including section 1860G).

1 “(b) PAYMENTS FOR ADDITIONAL ADMINISTRATIVE
2 COSTS.—

3 “(1) IN GENERAL.—The amounts expended by
4 a State in carrying out subsection (a) are, subject to
5 paragraph (2), expenditures reimbursable under the
6 appropriate paragraph of section 1903(a); except
7 that, notwithstanding any other provision of such
8 section, the applicable Federal matching rates with
9 respect to such expenditures under such section shall
10 be increased as follows (but in no case shall the rate
11 as so increased exceed 100 percent):

12 “(A) For expenditures attributable to costs
13 incurred during 2005, the otherwise applicable
14 Federal matching rate shall be increased by 10
15 percent of the percentage otherwise payable
16 (but for this subsection) by the State.

17 “(B)(i) For expenditures attributable to
18 costs incurred during 2006 and each subse-
19 quent year through 2013, the otherwise applica-
20 ble Federal matching rate shall be increased by
21 the applicable percent (as defined in clause (ii))
22 of the percentage otherwise payable (but for
23 this subsection) by the State.

24 “(ii) For purposes of clause (i), the ‘appli-
25 cable percent’ for—

1 “(I) 2006 is 20 percent; or

2 “(II) a subsequent year is the applica-
3 ble percent under this clause for the pre-
4 vious year increased by 10 percentage
5 points.

6 “(C) For expenditures attributable to costs
7 incurred after 2013, the otherwise applicable
8 Federal matching rate shall be increased to 100
9 percent.

10 “(2) COORDINATION.—The State shall provide
11 the Administrator with such information as may be
12 necessary to properly allocate administrative expend-
13 itures described in paragraph (1) that may otherwise
14 be made for similar eligibility determinations.”.

15 (b) PHASED-IN FEDERAL ASSUMPTION OF MEDICAID
16 RESPONSIBILITY FOR PREMIUM AND COST-SHARING SUB-
17 SIDIES FOR DUALY ELIGIBLE INDIVIDUALS.—

18 (1) IN GENERAL.—Section 1903(a)(1) (42
19 U.S.C. 1396b(a)(1)) is amended by inserting before
20 the semicolon the following: “, reduced by the
21 amount computed under section 1935(c)(1) for the
22 State and the quarter”.

23 (2) AMOUNT DESCRIBED.—Section 1935, as in-
24 serted by subsection (a)(2), is amended by adding at
25 the end the following new subsection:

1 “(c) FEDERAL ASSUMPTION OF MEDICAID PRE-
2 SCRIPTION DRUG COSTS FOR DUALY-ELIGIBLE BENE-
3 FICIARIES.—

4 “(1) IN GENERAL.—For purposes of section
5 1903(a)(1), for a State that is one of the 50 States
6 or the District of Columbia for a calendar quarter
7 in a year (beginning with 2005) the amount com-
8 puted under this subsection is equal to the product
9 of the following:

10 “(A) MEDICARE SUBSIDIES.—The total
11 amount of payments made in the quarter under
12 section 1860G (relating to premium and cost-
13 sharing prescription drug subsidies for low-in-
14 come medicare beneficiaries) that are attrib-
15 utable to individuals who are residents of the
16 State and are entitled to benefits with respect
17 to prescribed drugs under the State plan under
18 this title (including such a plan operating under
19 a waiver under section 1115).

20 “(B) STATE MATCHING RATE.—A propor-
21 tion computed by subtracting from 100 percent
22 the Federal medical assistance percentage (as
23 defined in section 1905(b)) applicable to the
24 State and the quarter.

1 “(C) PHASE-OUT PROPORTION.—The
 2 phase-out proportion (as defined in paragraph
 3 (2)) for the quarter.

4 “(2) PHASE-OUT PROPORTION.—For purposes
 5 of paragraph (1)(C), the ‘phase-out proportion’ for
 6 a calendar quarter in—

7 “(A) 2005 is 90 percent;

8 “(B) a subsequent year before 2014, is the
 9 phase-out proportion for calendar quarters in
 10 the previous year decreased by 10 percentage
 11 points; or

12 “(C) a year after 2013 is 0 percent.”.

13 (c) MEDICAID PROVIDING WRAP-AROUND BENE-
 14 FITS.—Section 1935, as so inserted and amended, is fur-
 15 ther amended by adding at the end the following new sub-
 16 section:

17 “(d) ADDITIONAL PROVISIONS.—

18 “(1) MEDICAID AS SECONDARY PAYOR.—In the
 19 case of an individual who is entitled to qualified pre-
 20 scription drug coverage under a prescription drug
 21 plan under part D of title XVIII (or under a
 22 Medicare+Choice plan under part C of such title)
 23 and medical assistance for prescribed drugs under
 24 this title, medical assistance shall continue to be pro-
 25 vided under this title for prescribed drugs to the ex-

1 tent payment is not made under the prescription
2 drug plan or the Medicare+Choice plan selected by
3 the individual.

4 “(2) CONDITION.—A State may require, as a
5 condition for the receipt of medical assistance under
6 this title with respect to prescription drug benefits
7 for an individual eligible to obtain qualified prescrip-
8 tion drug coverage described in paragraph (1), that
9 the individual elect qualified prescription drug cov-
10 erage under section 1860A.”.

11 (d) TREATMENT OF TERRITORIES.—

12 (1) IN GENERAL.—Section 1935, as so inserted
13 and amended, is further amended—

14 (A) in subsection (a) in the matter pre-
15 ceding paragraph (1), by inserting “subject to
16 subsection (e)” after “section 1903(a)”;

17 (B) in subsection (c)(1), by inserting “sub-
18 ject to subsection (e)” after “1903(a)(1)”; and

19 (C) by adding at the end the following new
20 subsection:

21 “(e) TREATMENT OF TERRITORIES.—

22 “(1) IN GENERAL.—In the case of a State,
23 other than the 50 States and the District of
24 Columbia—

1 “(A) the previous provisions of this section
2 shall not apply to residents of such State; and

3 “(B) if the State establishes a plan de-
4 scribed in paragraph (2) (for providing medical
5 assistance with respect to the provision of pre-
6 scription drugs to medicare beneficiaries), the
7 amount otherwise determined under section
8 1108(f) (as increased under section 1108(g))
9 for the State shall be increased by the amount
10 specified in paragraph (3).

11 “(2) PLAN.—The plan described in this para-
12 graph is a plan that—

13 “(A) provides medical assistance with re-
14 spect to the provision of covered outpatient
15 drugs (as defined in section 1860B(f)) to low-
16 income medicare beneficiaries; and

17 “(B) assures that additional amounts re-
18 ceived by the State that are attributable to the
19 operation of this subsection are used only for
20 such assistance.

21 “(3) INCREASED AMOUNT.—

22 “(A) IN GENERAL.—The amount specified
23 in this paragraph for a State for a year is equal
24 to the product of—

1 “(i) the aggregate amount specified in
2 subparagraph (B); and

3 “(ii) the amount specified in section
4 1108(g)(1) for that State, divided by the
5 sum of the amounts specified in such sec-
6 tion for all such States.

7 “(B) AGGREGATE AMOUNT.—The aggre-
8 gate amount specified in this subparagraph
9 for—

10 “(i) 2005, is equal to \$20,000,000; or

11 “(ii) a subsequent year, is equal to the
12 aggregate amount specified in this sub-
13 paragraph for the previous year increased
14 by annual percentage increase specified in
15 section 1860B(b)(5) for the year involved.

16 “(4) REPORT.—The Administrator shall submit
17 to Congress a report on the application of this sub-
18 section and may include in the report such rec-
19 ommendations as the Administrator deems appro-
20 priate.”.

21 (2) CONFORMING AMENDMENT.—Section
22 1108(f) (42 U.S.C. 1308(f)) is amended by inserting
23 “and section 1935(e)(1)(B)” after “Subject to sub-
24 section (g)”.

1 (e) AMENDMENT TO BEST PRICE.—Section
2 1927(c)(1)(C)(i) (42 U.S.C. 1396r–8(c)(1)(C)(i)) is
3 amended—

4 (1) by striking “and” at the end of subclause
5 (III);

6 (2) by striking the period at the end of sub-
7 clause (IV) and inserting “; and”; and

8 (3) by adding at the end the following new sub-
9 clause:

10 “(V) any prices charged which
11 are negotiated by a prescription drug
12 plan under part D of title XVIII, by
13 a Medicare+Choice plan under part C
14 of such title with respect to covered
15 outpatient drugs, or by a qualified re-
16 tiree prescription drug plan (as de-
17 fined in section 1860H(f)(1)) with re-
18 spect to such drugs on behalf of indi-
19 viduals entitled to benefits under part
20 A or enrolled under part B of such
21 title.”.

22 **SEC. 104. MEDIGAP TRANSITION.**

23 (a) IN GENERAL.—Section 1882 (42 U.S.C. 1395ss)
24 is amended by adding at the end the following new sub-
25 section:

1 “(v) COVERAGE OF PRESCRIPTION DRUGS.—

2 “(1) IN GENERAL.—Notwithstanding any other
3 provision of law, except as provided in paragraph (3)
4 no new medicare supplemental policy that provides
5 coverage of expenses for prescription drugs may be
6 issued under this section on or after January 1,
7 2005, to an individual unless it replaces a medicare
8 supplemental policy that was issued to that indi-
9 vidual and that provided some coverage of expenses
10 for prescription drugs.

11 “(2) ISSUANCE OF SUBSTITUTE POLICIES IF
12 OBTAIN PRESCRIPTION DRUG COVERAGE UNDER
13 PART D.—

14 “(A) IN GENERAL.—The issuer of a medi-
15 care supplemental policy—

16 “(i) may not deny or condition the
17 issuance or effectiveness of a medicare
18 supplemental policy that has a benefit
19 package classified as ‘A’, ‘B’, ‘C’, ‘D’, ‘E’,
20 ‘F’, or ‘G’ (under the standards estab-
21 lished under subsection (p)(2)) and that is
22 offered and is available for issuance to new
23 enrollees by such issuer;

24 “(ii) may not discriminate in the pric-
25 ing of such policy, because of health sta-

1 tus, claims experience, receipt of health
2 care, or medical condition; and

3 “(iii) may not impose an exclusion of
4 benefits based on a pre-existing condition
5 under such policy,

6 in the case of an individual described in sub-
7 paragraph (B) who seeks to enroll under the
8 policy not later than 63 days after the date of
9 the termination of enrollment described in such
10 paragraph and who submits evidence of the
11 date of termination or disenrollment along with
12 the application for such medicare supplemental
13 policy.

14 “(B) INDIVIDUAL COVERED.—An indi-
15 vidual described in this subparagraph is an in-
16 dividual who—

17 “(i) enrolls in a prescription drug plan
18 under part D; and

19 “(ii) at the time of such enrollment
20 was enrolled and terminates enrollment in
21 a medicare supplemental policy which has
22 a benefit package classified as ‘H’, ‘I’, or
23 ‘J’ under the standards referred to in sub-
24 paragraph (A)(i) or terminates enrollment
25 in a policy to which such standards do not

1 apply but which provides benefits for pre-
2 scription drugs.

3 “(C) ENFORCEMENT.—The provisions of
4 paragraph (4) of subsection (s) shall apply with
5 respect to the requirements of this paragraph in
6 the same manner as they apply to the require-
7 ments of such subsection.

8 “(3) NEW STANDARDS.—In applying subsection
9 (p)(1)(E) (including permitting the NAIC to revise
10 its model regulations in response to changes in law)
11 with respect to the change in benefits resulting from
12 title I of the Medicare Modernization and Prescrip-
13 tion Drug Act of 2002, with respect to policies
14 issued to individuals who are enrolled under part D,
15 the changes in standards shall provide only provide
16 for substituting for the benefit packages that in-
17 cluded coverage for prescription drugs two benefit
18 packages that may provide for coverage of cost-shar-
19 ing with respect to qualified prescription drug cov-
20 erage under such part, except that such coverage
21 may not cover the prescription drug deductible
22 under such part. The two benefit packages shall be
23 consistent with the following:

24 “(A) FIRST NEW POLICY.—The policy de-
25 scribed in this subparagraph has the following

benefits, notwithstanding any other provision of this section relating to a core benefit package:

“(i) Coverage of 50 percent of the cost-sharing otherwise applicable, except coverage of 100 percent of any cost-sharing otherwise applicable for preventive benefits.

“(ii) No coverage of the part B deductible.

“(iii) Coverage for all hospital coinsurance for long stays (as in the current core benefit package).

“(iv) A limitation on annual out-of-pocket expenditures to \$4,000 in 2005 (or, in a subsequent year, to such limitation for the previous year increased by an appropriate inflation adjustment specified by the Secretary).

“(B) SECOND NEW POLICY.—The policy described in this subparagraph has the same benefits as the policy described in subparagraph (A), except as follows:

“(i) Substitute ‘75 percent’ for ‘50 percent’ in clause (i) of such subparagraph.

1 “(ii) Substitute ‘\$2,000’ for ‘\$4,000’
2 in clause (iv) of such subparagraph.

3 “(4) CONSTRUCTION.—Any provision in this
4 section or in a medicare supplemental policy relating
5 to guaranteed renewability of coverage shall be
6 deemed to have been met through the offering of
7 other coverage under this subsection.”.

8 **SEC. 105. MEDICARE PRESCRIPTION DRUG DISCOUNT**
9 **CARD ENDORSEMENT PROGRAM.**

10 Title XVIII is amended by inserting after section
11 1806 the following new section:

12 “MEDICARE PRESCRIPTION DRUG DISCOUNT CARD
13 ENDORSEMENT PROGRAM

14 “SEC. 1807. (a) IN GENERAL.—The Secretary (or
15 the Medicare Benefits Administrator pursuant to section
16 1808(c)(3)(C)) shall establish a program—

17 “(1) to endorse prescription drug discount card
18 programs that meet the requirements of this section;
19 and

20 “(2) to make available to medicare beneficiaries
21 information regarding such endorsed programs.

22 “(b) REQUIREMENTS FOR ENDORSEMENT.—The
23 Secretary may not endorse a prescription drug discount
24 card program under this section unless the program meets
25 the following requirements:

1 “(1) SAVINGS TO MEDICARE BENEFICIARIES.—

2 The program passes on to medicare beneficiaries
3 who enroll in the program discounts on prescription
4 drugs, including discounts negotiated with manufac-
5 turers.

6 “(2) PROHIBITION ON APPLICATION ONLY TO

7 MAIL ORDER.—The program applies to drugs that
8 are available other than solely through mail order.

9 “(3) BENEFICIARY SERVICES.—The program

10 provides pharmaceutical support services, such as
11 education and counseling, and services to prevent
12 adverse drug interactions.

13 “(4) INFORMATION.—The program makes

14 available to medicare beneficiaries through the Inter-
15 net and otherwise information, including information
16 on enrollment fees, prices charged to beneficiaries,
17 and services offered under the program, that the
18 Secretary identifies as being necessary to provide for
19 informed choice by beneficiaries among endorsed
20 programs.

21 “(5) DEMONSTRATED EXPERIENCE.—The enti-

22 ty operating the program has demonstrated experi-
23 ence and expertise in operating such a program or
24 a similar program.

1 “(6) QUALITY ASSURANCE.—The entity has in
2 place adequate procedures for assuring quality serv-
3 ice under the program.

4 “(7) ADDITIONAL BENEFICIARY PROTEC-
5 TIONS.—The program meets such additional require-
6 ments as the Secretary identifies to protect and pro-
7 mote the interest of medicare beneficiaries, including
8 requirements that ensure that beneficiaries are not
9 charged more than the lower of the negotiated retail
10 price or the usual and customary price.

11 “(c) PROGRAM OPERATION.—The Secretary shall op-
12 erate the program under this section consistent with the
13 following:

14 “(1) PROMOTION OF INFORMED CHOICE.—In
15 order to promote informed choice among endorsed
16 prescription drug discount card programs, the Sec-
17 retary shall provide for the dissemination of infor-
18 mation which compares the costs and benefits of
19 such programs in a manner coordinated with the
20 dissemination of educational information on
21 Medicare+Choice plans under part C.

22 “(2) OVERSIGHT.—The Secretary shall provide
23 appropriate oversight to ensure compliance of en-
24 dorsed programs with the requirements of this sec-

1 tion, including verification of the discounts and serv-
2 ices provided.

3 “(3) USE OF MEDICARE TOLL-FREE NUMBER.—

4 The Secretary shall provide through the 1-800-medi-
5 care toll free telephone number for the receipt and
6 response to inquiries and complaints concerning the
7 program and programs endorsed under this section.

8 “(4) DISQUALIFICATION FOR ABUSIVE PRAC-

9 TICES.—The Secretary shall revoke the endorsement
10 of a program that the Secretary determines no
11 longer meets the requirements of this section or that
12 has engaged in false or misleading marketing prac-
13 tices.

14 “(5) ENROLLMENT PRACTICES.—A medicare

15 beneficiary may not be enrolled in more than one en-
16 dorsed program at any time.

17 “(d) TRANSITION.—The Secretary shall provide for
18 an appropriate transition and discontinuation of the pro-
19 gram under this section at the time prescription drug ben-
20 efits first become available under part D.

21 “(e) AUTHORIZATION OF APPROPRIATIONS.—There

22 are authorized to be appropriated such sums as may be
23 necessary to carry out the program under this section.”.

1 **SEC. 106. GAO STUDY OF THE EFFECTIVENESS OF THE NEW**
2 **PRESCRIPTION DRUG PROGRAM.**

3 (a) STUDY.—The Comptroller General of the United
4 States shall conduct a study on the effectiveness of the
5 prescription drug program provided under part D of title
6 XVIII of the Social Security Act. Such study shall—

7 (1) report—

8 (A) the percentage of eligible individuals
9 who enrolled in the program;

10 (B) the demographic characteristics (in-
11 cluding health status) of such enrollees;

12 (C) the number and type of qualified pre-
13 scription drug coverage available to such indi-
14 viduals (including the percentage of enrollees
15 who had access to single or multiple plans); and

16 (D) the premiums imposed for enrollment
17 in different areas;

18 (2) evaluate the processes and methods devel-
19 oped by the Administrator and the decisions reached
20 by outside actuaries to determine the actuarial valu-
21 ation of prescription drug coverage; and

22 (3) assess whether the subsidy payments under
23 such part accomplished its stated goals of reducing
24 premium levels for all beneficiaries, reducing adverse
25 selection, and promoting participation of PDP spon-
26 sors.

1 (b) REPORT.—Not later January 1, 2006, the Comp-
2 troller General shall submit a report to Congress on the
3 study conducted under subsection (a).

Union Calendar No. 330

107TH CONGRESS
2^D SESSION

H. R. 4984

[Report No. 107-551, Part 1]

A BILL

To amend title XVIII of the Social Security Act to
provide for a medicare prescription drug benefit.

JUNE 28, 2002

Committee on Ways and Means discharged; committed to
the Committee of the Whole House on the State of the
Union and ordered to be printed